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Eliciting adverse event (AE) and non-study medication reports from clinical research 
participants is integral for evaluating drug safety. However, using different methods to 
question participants yields inconsistent results, compromising the interpretation, 
comparison and pooling of data across studies. This is particularly important given the 
widespread use of antimalarials in vulnerable populations, and their increasing use in 
healthy but at-risk individuals as preventive treatment or to reduce malaria transmission.  
 
Experienced, qualified antimalarial drug clinical researchers were invited to participate in 
a Delphi process, to facilitate consensus on what panellists consider to be optimal (relevant, 
important and feasible) methods, tools, and approaches for detecting participant-reported 
AE and non-study medication data in uncomplicated malaria treatment studies. 
 
This Delphi built on a previous survey conducted among malaria clinical researchers about 
different elicitation methods they used. The findings thereof, and a summary of relevant 
literature, were presented to Delphi panellists in round one after which they were asked to 
suggest further questioning methods or approaches that they considered as important and 
feasible for asking participants (or their caregivers) about their health to collect adverse 
events, and use of non-study medications to collect previous or concomitant medication 
data. 
 
In round two, the panellists were presented with the collated suggestions from round one to rate 
each type of question in terms of its relevance, importance and feasibility. Here, panellists would 
rate methods or approaches as either optimal or not optimal for inclusion in a 'menu' of harmonized 




In round three, panellists were presented with a summary of items which had achieved consensus 
in round two and, for items that had not achieved consensus they were asked whether or not they 
wished to change their response in view of the group’s overall response. 
Of the 72 invited, 25; 16 and 10 panellists responded to the first, second and third rounds 
of the Delphi process respectively. Overall, 68% of all questioning items presented for 
rating achieved consensus. When asking general questions about health, panellists agreed 
to include a question/concept about any change in health, taking care to ensure that such 
questions/concepts do not imply causality.  Eighty-nine percent (39/44) of structured items 
about specific signs and symptoms, were rated as optimal. For non-study medications, a 
general question and most structured questioning items were considered an optimal 
approach. The use of mobile phones, patient diaries, rating scales as well as openly 
engaging with participants to discuss concerns were also considered optimal 
complementary data-elicitation tools.  
This study succeeded in reaching consensus within a section of the antimalarial drug 
clinical research community about using a general question concept, and some structured 
questions for eliciting data about AEs and non-study medication reports. The findings 
suggest that one method of questioning may not be superior to another, or sufficient to 
fulfil its purpose on its own and that the use of a combination of methods may be optimal. 
As malaria clinical research is often conducted in children (and other vulnerable groups), this 
becomes an important consideration in the design of appropriate elicitation methods cognisant of 
any particular factors that may impede accurate reporting in these groups. 
The concepts and items found in this Delphi survey to be relevant, important and feasible 




participant-elicited antimalarial drug safety data. This, in turn, should improve 
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PART A:  RESEARCH PROTOCOL 
DEVELOPMENT OF HARMONISED APPROACHES FOR DETECTING 
AND RECORDING PARTICIPANT-REPORTED  
1. SYNOPSIS
Background 
The information clinical trial participants report about their health and use of non-trial 
treatments that become adverse event and previous/concomitant medication data is 
influenced by the questioning method used. There is no consensus on how participants 
should be questioned about these data during malaria clinical trials/studies. Following 
relevant methodological research we have conducted in this field we will now invite 
experts in antimalarial clinical drug research to work towards consensus about the 
appropriate design of relevant and feasible methods to question participants about their 
health and previous/concomitant medications. 
Objective 
To use a Delphi process to work towards building consensus on the appropriate 
methods and/or tools to use to detect adverse event and previous/concomitant 
medication data in malaria clinical trials/studies. The current research aims to be the 
beginning of dialogue among antimalarial drug clinical researchers, which would 
eventually lead to the development of an optimised universal AE data capturing tool 




Study design and methods 
Population and sampling 
Delphi panellists must meet inclusion criterion such that they have the relevant 
experience in the elicitation of adverse event and concomitant medication data from 
participants within malaria clinical trials/studies. For this study this criteria will 
include any of the following: clinical investigators with responsibility for a clinical 
trial/study where such data have been collected, those with responsibility for the 
selection, design, review or testing of tools to collect such data, those directly involved 
in the elicitation (questioning) and recording of such data from participants, those 
fulfilling a drug regulatory role as regards the review of clinical trial/study data, and 
representatives of sponsors funding and/or conducting malaria clinical studies/trials. 
To recruit panellists we will use purposive sampling to select appropriate participants 
of our recent survey about methods used in antimalarial studies/trials to elicit, assess 
and record these data. We will also send invitations to individuals known to us who 
have knowledge relevant to the research. Self-selection will ultimately determine who 
responds and participates. The minimum sample size we anticipate, based on Delphi-
related literature, will be twenty panellists completing the last round. 
  
Delphi design, pilot and conduct 
The Delphi will be conducted online with the identity of panellists remaining 
anonymous to each other and the investigators to ensure that ideas, opinions and 
thoughts contributed by individuals are not subject to intimidation, or undue influence. 
There will be three to five rounds of questionnaires. The first round will consist of 
open-ended questions to allow participants to comment broadly on the research topic. 
Questions in subsequent rounds will be more specific and aim to quantify responses 




summarised and presented to panellists and they will then be asked to comment on 
their level of agreement with the results. Rating will be achieved using a nine-point 
Likert scale with options from ‘strongly agree’ to ‘strongly disagree’ Consensus will 
be defined  as having no less than 70 % of panellists selecting options which are within 
a three-point region containing the median. 
   
Study data management and synthesis 
Responses will be housed in suitable software. Descriptive statistics of responses to 
closed questions will be presented in tables or graphs, while open responses will be 
explored thematically.  
 
Ethical considerations 
The Delphi is assessed as minimal/everyday risk however concerns about 
confidentiality issues will be addressed by ensuring the anonymity of respondents. All 
panelists will be assigned unique identifiers which will be stored electronically and in 
paper files and be accessed by only one specific member of the research team who will 
not be involved in data collection and analysis. Participant’s identity will not be used 





The ACT Consortium is a group of researchers conducting projects relating to the 
implementation of Artemisinin-based combination therapies (ACT) for malaria 
treatment within Africa and Asia (www.actconsortium.org). The Liverpool School of 
Tropical Medicine has developed a customised database that will enable all relevant 
ACT Consortium studies, and projects outside of the ACT Consortium, to contribute 
their harms data. This is because the pooling of harms data may be used to generate 
signals of new, possibly rare, adverse drug reactions (ADRs) or identify the incidence 
of known ADRs with greater statistical certainty (Strom, 2005; FDA, 2005). The 
information about health reported by clinical trial participants in order to collect 
adverse event (AE) data is, however, highly influenced by questioning methods 
(Ioannidis et al, 2006). To date, there is no consensus on how participants should be 
questioned about their health, or how staff should then assess and/or record the data 
elicited. The results of individual studies, and therefore syntheses of reports, and 
analyses of pooled individual participant harms data are then all influenced by the 
methods used to collect such data. Symptoms are often elicited during unstructured 
discussions involving general open enquiries about health, while some projects use 
detailed, structured elicitation approaches, including checklists by symptom or body 
function. There is evidence that more detailed methods increase the sensitivity of 
detecting participant-reported AEs, though their effect on the nature of reports is less 
clear (Bent et al, 2006). There are concerns, for instance, that detailed methods could 
produce a deluge of ‘noise’, unhelpful AEs that cannot, for instance, be distinguished 
from background rates, and that spontaneously reported events are either more 
clinically meaningful or more likely to be related to a trial drug compared to placebo 




the detection and recording of participant-reported medical history and concomitant 
medication data in clinical trials, even though they are also integral to a safety 
evaluation. However, methodological studies in other areas of pharmacoepidemiology 
show that these data are also subject to the methods used to detect them (Strom, 2005). 
 
Further to this, the processes which research staff use to record information about the 
health and treatments reported by trial participants is seldom standardised and can 
therefore cause further inconsistencies within or between datasets. In particular there 
are concerns about selection bias of participant AE reports, whereby clinical trial staff 
inadvertently downgrade participant reports (Basch, 2010).  
 
Our first ACT Consortium project (SEACAT 2.5.1, UCT REC Ref: 376/2009) 
explored the process of participant-reported AE and concomitant medication data 
elicitation in two malaria and human immunodeficiency virus (HIV) drug interaction 
clinical trials, including whether, and if so why, certain questioning techniques fail to 
detect some data in this therapeutic area. Participant reports obtained through three 
different questioning types (a general enquiry followed by a structured enquiry using 
checklists of possible health issues and treatments and finally an in-depth interview) 
were compared. We used qualitative methods to explore participants’ experiences of 
illness and treatment, and their reporting behaviour. There was an overall increase in 
the number of reports from general enquiry, through checklists, to in-depth interview. 
Using checklists and interviews appeared to facilitate recognition of health issues and 
treatments, and consideration of what to report. Information was sometimes not 
reported initially because participants either forgot, the event or treatment had low 
significance to them, it was considered not relevant, or because of perceived negative 




citizenship”, working to achieve the researchers’ goals, compared to Tanzanian 
outpatients who sometimes deferred responsibility for identifying which items to 
report to the trial doctor. The different trial contexts appeared to cultivate some specific 
conditions that had a role in mediating recognition, reporting and articulation of these 
important variables. We proposed that some barriers to reporting in trials may be 
overcome by using a checklist, other barriers may require a different approach, such 
as counseling participants to quell potential concerns about reporting.  
 
In a second ACT Consortium project we have surveyed methods used by antimalarial 
clinical drug researchers to elicit, record and assess participant-reported AEs, medical 
histories and treatment-use (SEACAT 2.5.1, UCT REC Ref: 376/2009). In parallel we 
are conducting a Cochrane systematic review that will formally assess the literature on 
comparisons of methods used within or specific for, clinical drug trials (in general) to 
elicit information from participants about AEs. We will now present a summary of the 
relevant literature to experts in the field of malaria clinical research and invite them to 
work towards consensus about the appropriate design of relevant and feasible 
elicitation methods to detect these important participant-reported data. This protocol 
describes how this will be achieved using a Delphi Process. 
 
2.2 Study rationale  
Developing optimal tools with which to capture participant-reported safety data in 
malaria drug research requires further work. We believe it is important to locate this 
work within a broad framework of harmonised approaches for eliciting, assessing and 
recording participant-reported antimalarial safety data and this work could augment 




We hope that using the Delphi will generate input and buy-in of those who could 
ultimately be using such harmonised methods, and also foster collaborations for the 
future testing of these methods. The overall project (empirical research, survey, 
Cochrane review and the Delphi) reflects our observations of how researchers in other 
therapeutic areas are working towards the same goals as regards harmonisation of 
methods used in recording safety or other health-related data (Booth et al, 2011; Basch, 
2011; Woodworth et al, 2007). The ACT Consortium is in a good position to facilitate 
collaboration between those working in malaria clinical research and we consider this 
project to be valuable as it would enhance the field and contribute to safer use of anti-
malarials in key target populations. 
3. STUDY AIM AND OBJECTIVES
3.1 General aim 
The overall aim of the SEACAT 2.5.1 project is to contribute to the development of 
harmonised approaches for detecting and recording participant-reported antimalarial 
drug safety data. 
3.2 Objectives 
The objective of this specific protocol (SEACAT 2.5.1 Extension Part 3: The Delphi 
Process) is to select and/or design, by consensus, appropriate and feasible methods or 
tools for detecting participant-reported AE and concomitant medication data in a 




4. STUDY DESIGN AND METHODS 
4.1  Study design 
We will use a Delphi study to aid in the choice or design, by consensus, of appropriate 
and feasible methods/tools for detecting participant-reported AE and concomitant 
medication data in a variety of contexts, for future testing. The use of Delphi, which 
was developed in the 1950s by the RAND Corporation (Linstone & Turoff, 1975) 
involves soliciting opinion from those with relevant expertise in a particular area with 
the aim of achieving consensus of opinion on a particular topic. The Delphi is a 
multistage process characterised by controlled feedback to panellists at each round 
based on results of previous rounds (Sumsion, 1998). Consensus is reached through 
this feedback mechanism as panellists are presented with a summary of the group’s 
perspectives along with their own. They are then asked if they would like to change 
their response to agree with the majority or to maintain their original opinion. A 
characteristic feature of the Delphi is that participants remain anonymous to each other 
to avoid domination by any one participant and also to allow panellists complete 
freedom of expression (Sinha et al, 2011; Boulkedid  et al, 2011). Delphi methodology 
is frequently adapted according to the research aim and for practical circumstances 
(Booth et al, 2011; de Meyrick, 2003). The design for this Delphi study is largely based 
on the findings of two systematic reviews of Delphi methods used to determine clinical 
trial outcomes and health quality indicators (Sinha et al, 2011; Boulkedid et al, 2011). 
Other publications which offer guidelines to health researchers on how to effectively 
use the Delphi technique have also been used (Hasson et al, 2000; Sumsion, 1998; de 
Meyrick, 2003; Clibbens et al, 2011).  
 
An advantage of using the Delphi is that panellists do not have to be in the same 




distributed remotely (Sumsion, 1998; de Meyrick, 2003). In addition, the nature of the 
study design ensures that individual’s opinions can be considered in a non-adversarial 
manner allowing them to fully express themselves without reservation or fear of 
condemnation or ridicule (Boulkedid et al, 2011; Hasson et al, 2000). However, as 
selection of participants required in the process is purposive, this opens this type of 
study to selection bias. Furthermore, the selection of participants who have a vested 
interest in the study findings and who may be directly affected by the results of the 
Delphi may introduce subject bias as well. Because of this, it is particularly important 
to ensure that panellists selected for the Delphi have an interest in the research topic 
but remain relatively impartial so that their opinions are informed by current 
knowledge and practices (Hasson et al, 2000). Panellists for this Delphi will be 
selected from various disciplinary backgrounds to reduce the impact of subject bias 
and ensure as far as possible that true consensus is reached. In an attempt to prevent 
subject bias, effort will be made to include (and retain) at least 10% of panellists whose 
work is not directly influenced by the outcomes of the Delphi process, for instance 
those from regulatory agencies (Hasson et al, 2000). 
 
4.2 Population and sampling  
4.2.1 Population  
Participation in the Delphi will be limited to individuals who are considered as 
‘experts’ in the area of antimalarial clinical drug trials/studies. Participation will be 
limited in this way to ensure that individuals who are included as panellists have the 
relevant knowledge and expertise to contribute positively to the research process 
(Sinha et al, 2011; de Meyrick, 2003). For the purposes of our current research work, 
the term ‘expert’ will refer to anyone who meets one or more of the following criteria 
for antimalarial drug research: 
___________________________________________________________Research Protocol 
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i) A clinical investigator who has had responsibility for a clinical trial/study
where AE and/or concomitant medication data have been collected as part of
the protocol.
ii) Someone who has had responsibility for the selection, design, review or testing
of tools to collect clinical trial/study AE and/or concomitant medication data.
iii) Someone who is directly involved in the elicitation (questioning) and recording
of AE and concomitant medication data from participants within malaria
clinical trials/studies.
iv) Someone who fulfils a drug regulatory role as regards the review of clinical
trial/study data, whether pre- or post-marketing.
v) A representative of a sponsor who has funded and/or conducted malaria clinical
trials.
4.2.2 Sampling 
Sampling for the Delphi will be active, using non-probability sampling techniques, 
specifically purposive sampling. This will enable us to ensure that those who are 
invited to be panellists in the Delphi will meet our inclusion criteria. The use of 
purposive sampling may also reduce attrition as we will mostly, but not entirely, target 
individuals who have a vested interest in the outcomes of the research. To try and 
prevent biasing the outcomes of the Delphi by including such panellists, we will try to 
ensure that at least 10 % of panellists are individuals who are knowledgeable on the 
subject matter but are not directly affected by the outcomes of the research. Survey 
respondents from a previous phase of this project will be assessed to determine 
whether or not they meet the inclusion criteria (as stated above), and invitations to take 
part in the Delphi will be sent to those individuals directly. Though we do not consider 




voice will be represented by way of incorporating a summary of the results of 
interviews and focus group discussions held with antimalarial clinical trial participants 
in our ACT Project 16 Phase 1, when they were asked for suggestions as to how the 
clinical trial team could get the most (and accurate) information on their health and 
treatments. 
 
We will also actively invite all ACT Consortium Principal Investigators (or their 
designee), and investigators from other antimalarial clinical research organisations, 
such as MiP Consortium, who are involved in clinical studies where AEs and/or 
concomitant medication data are elicited from participants. Contacts known to the 
researchers as representatives from organisations that research and develop anti-
malarial drugs (e.g. Medicines for Malaria Venture, Drugs for Neglected Diseases 
Initiative, and pharmaceutical companies) will be approached and invited to 
participate. We will also send invitations to representatives from regulatory authorities 
known to review malaria clinical trial data.  
 
All those identified as possible panellists will be sent an invitational email explaining 
the purpose of the research, what is expected of panellists and asking them to 
participate in the process. Self-selection by those invited will ultimately determine who 
responds and participates. Emails containing an automatic link to the online Delphi 
site will be sent to those individuals who agree to take part.  
 
4.2.3 Sample size 
There are no clear guidelines on what constitutes a suitable sample size for a Delphi 
Process. Recommendations are that the researcher should be guided by the research 




1998). Large sample sizes are not favourable as they raise issues with regards to data 
handling and potential analysis difficulties as well as resource constraints (Sumsion, 
1998; Hasson et al, 2000) On the other hand, sample sizes which are too small may 
yield results which lack significance and are not very useful. It has been found that 
reliable outcomes in a Delphi process can be obtained with a sample size as small as 
twenty three panellists given that they are selected using stringent inclusion criteria 
(Akins et al, 2005). According to Akins, the sample size of a Delphi panel is not a 
statistically-bound parameter and good results can still be obtained using a 
comparatively small group of even homogenous experts. Considering our highly 
specific definition of an ‘expert’ and anticipating attrition at each round, we will not 
set a limit to the maximum number of participants who take part and no sample size 
calculation will be done. The intention is for the Delphi process to be as broad and 
inclusive as possible within the limitations set for the study population. The minimum 
sample size we anticipate, given criteria already mentioned, will be twenty panellists 
completing the last round. 
 
4.3 Delphi conduct 
Questionnaires to elicit panellist opinions will be designed and administered through 
Surveygizmo (or equivalent). Online completion of the questionnaires will ensure 
that panellists remain anonymous to each other and also to the researchers analysing 
the data set.  
 
The Delphi will be comprised of an anticipated three to five rounds, each aimed at 
generating a higher degree of consensus among panellists about appropriate and 
feasible methods or tools for detecting participant-reported AE and concomitant 




In the first round the group will be presented with a summary of the literature of this 
field of research, including our own empirical research, survey and systematic review 
results. Our own work may be preliminary or unpublished at the time of starting the 
Delphi and will be indicated as such. We consider it justifiable to include our own 
work in this way as there is a dearth of relevant research. This therefore ensures that 
novel concepts about the role of subjectivity as regards the measurement of harms data 
in malaria clinical research (an area devoid of evidence in the literature to date), current 
methods used to detect such data and the opinions of some of the malaria community 
about these issues are available.   
In the first round, Delphi panellists will be asked open-ended questions about what 
they consider as optimal approach(es) for asking participants (or caregivers) about 
their health and use of non-study treatments to collect medical history, AE and 
concomitant medication data in different studies and contexts. There will be room for 
free-text comments and suggestions of further methods or considerations pertinent for 
this complex field.  A draft is provided in Appendix 3, to be piloted before finalisation 
as indicated below.  
 
In the second round each approach, method or component generated in the first round 
will be presented to panellists for rating in terms of their level of agreement of the 
importance and feasibility for detecting participant-reported AEs, medical history and 
concomitant medications. Rating will be achieved using a nine-point Likert scale with 
options from ‘strongly agree’ to ‘strongly disagree’.  
 
In subsequent rounds, each panellist will be sent a summary of the previous round’s 
results in the form of descriptive statistics presented in tables or graphs. They will also 




they deviate from the majority, or indicate if they prefer to maintain their original 
opinion and state why (Clibbens et al, 2012). The Delphi will be stopped when 
consensus is achieved in each area of elicitation. Consensus will be defined (similarly 
to the Rand UCLA criteria for agreement as described by Fitch et al, 2001) as having 
no less than 70 % of panellists selecting options which are within the  three-point 
region (1-3, 4-6, 7-9) containing the median (Boulkedid et al, 2011; Clibbens et al, 
2012; Boulkedid et al, 2011). 
 
4.4 Data management 
Responses from all rounds will be downloaded from the website and housed in a 
suitable data management program, such as NVivo® (QSR International Pty Ltd) for 
qualitative data or Microsoft Excel® for quantitative data. The first round will 
incorporate open-ended questions which will aim to be as exhaustive as possible in 
exploring the concepts of interest. Relevant descriptive text will be examined for 
recurring ideas, which will be labelled and grouped into themes reflecting the 
underlying meaning or concepts behind statements (Auerbach & Silverstein, 2003; 
Strauss & Corbin, 1990). Descriptive statistics of responses to the closed survey 
questions will be presented in tables or graphs, and we will calculate median values of 
responses in the second and subsequent rounds. 
 
4.5 Validity and reliability 
There will be a pilot of all rounds of the survey with approximately five malaria clinical 
drug researchers. These individuals will be invited to log-on to the website and 
complete the Delphi questionnaires. Afterwards they will be contacted by a member 
of the research team and asked to provide feedback on the process. To help ensure face 




understood (that is to say questions were understood as intended by the researchers), 
unambiguous and complete (Sumsion, 1998). We will also ask the panellists to 
comment on whether there are additional items worth including, to help ensure content 
validity. Any necessary adjustments to the questionnaires will then be made. The pilot 
study will produce guidelines on the expected length of time it will take to fully 
complete the questionnaires in each round (de Meyrick, 2003). While the data elicited 
in the pilot will not be incorporated into the final results, the pilot group will be able 
to take part in the actual Delphi as this is a small field of research.  
 
The Delphi can be time consuming and require prolonged involvement of panellists. 
As a result, they may lose motivation to remain in the Delphi and drop out before they 
complete the final round. This may result in attrition bias, especially if those who drop 
out have some common characteristic. The importance of completing the whole Delphi 
process, which may mean considerable involvement by participants, and the proposed 
benefit to the area of malarial clinical research of the outcome will be emphasised to 
panellists from the start to reduce attrition.  
 
We will also address the issue of attrition bias by including participants with a vested 
interest in the current research work (malaria clinical trialists) who are directly or 
indirectly affected by the research question we are addressing. We will stress the 
importance of remaining impartial and objective in their contributions to these 
panellists to minimise the effect of subject bias. Panellists who do not respond by the 
allocated date will be prompted individually via email to ensure our response rate does 
not fall below the recommended 70 % in each round to ensure the rigour of the Delphi 




To avoid researcher bias, the study investigators will be blinded to the identity of the 
panellists. Panellists will be given unique identifying codes which will only be known 
by a research associate who will be responsible for following up with non-responders 
to encourage them to complete the questionnaire at each round of the Delphi. Subject 
bias will be minimised by the anonymous nature of the Delphi which overcomes the 
biasing influences of personality, seniority, experience and group domination by 
individuals (Hardy et al, 2003). 
 
By ensuring we maintain strict criteria in the definition of an ‘expert’, selection of 
panelists, heterogeneity of disciplinary backgrounds of the expert panelists and 
definition of consensus prior to data collection and analysis, we will add to the validity 
of the consensus findings of the research (Hardy et al, 2003). 
 
5. ETHICAL CONSIDERATIONS 
5.1 Risks and benefits 
The Delphi process has been assessed by the investigational team as minimal/everyday 
risk. Notwithstanding, there may be potential concerns for respondents as regards, for 
instance, confidentiality. The project therefore addresses this particular concern in its 
introduction, and advises potential respondents that there is no obligation to take part 
at all and they are free to withdraw at any time. Panelists will benefit from participatory 
discussion with other malaria clinical trial researchers with considerable experience 
and expertise in this field of research. Through this discussion and sharing of 
information their own research and knowledge may be enhanced. A disadvantage in 
participating in the Delphi is that it can often be time consuming and requires 




however kept our questions as brief as possible while still ensuring the richness of data 
collected 
 
5.2 Ethical approvals 
Written approval of this protocol will be requested from the University of Cape Town, 
Faculty of Health Sciences Health Research Ethics Committee before the pilot phase 
starts. The final version of the questionnaires to be used will be submitted to the ethics 
committee after the pilot phase. 
 
5.3 Subject information and informed consent 
Consent to take part in this online Delphi process will be assumed as integral with its 
completion and submission. Therefore there is no informed consent process or 
documentation other than a check box at the start of the Delphi that participants signal 
their consent to continue. 
 
5.4 Confidentiality 
Responses held on the Surveygizmo® website, or otherwise, will be kept secure (either 
electronically by way of password protection or through lockable physical filing 
systems), with access restricted to a research associate who is not part of the 
investigational team. Once the study is completed the panelists will be identified to the 
investigators in order to conduct the draw and invite them to subsequent meetings to 
discuss the findings. Panelists will also be asked if they would like to be acknowledged 
in any publication(s). However, at no point will individual responses to Delphi 
questions be made available to the investigators, as links between identifiers and 
responses will be disabled before the results are made available. At the end of the 




the investigational team, other panelists or in publications or subsequent follow-up 
activities.  
 
6. ADMINISTRATION  
6.1 Adherence to the protocol 
The study will be conducted in compliance with the final version of the approved 
protocol. Should any additions or changes to the protocol be deemed necessary, re-
approval will be requested from the research ethics committee. 
 
6.2 Record keeping 
At the outset of this study the project team will set up secure electronic and paper-
based filing systems to keep all study-specific information. This will be retained for 5 
years after publication. 
 
6.3 Publication of results 
Results are planned to be published in a peer review scientific journal with Ms 
Nyaradzo Mandimika as the primary author.  Other authorships will be mutually 
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PART B:  LITERATURE REVIEW 
1. INTRODUCTION 
In 2015, malaria accounted for 438,000 deaths globally, with 90 % of these deaths 
occurring in the World Health Organisation Africa region (WHO, 2015). Although 
malaria is no longer the leading cause of death in children, having dropped from 
723,000 deaths in 2000 to 306,000 in 2015 globally, it still remains a significant cause 
of death in children under the age of five, particularly in Sub-Saharan Africa where 
292,000 deaths occurred in 2015 (WHO, 2015). Similarly, there has been a 48 % 
overall decrease in malaria-related mortality rates worldwide since 2000, however, it 
is concerning to note increasing evidence of malaria parasite resistance to many of the 
drugs currently being used in the fight against malaria (WHO, 2015; Hopkins-Sibley, 
2014).  It is estimated that African countries lose US$ 12 billion yearly as a result of 
lost productivity and the gross domestic product (GDP) recedes by 1.3 % every year 
in the worst affected countries due to malaria disease (World Bank, 2009). 
Furthermore, in countries where malaria is endemic, as much as 40 % of the public 
sector expenditure for health is utilised for treatment of malaria (World Bank, 2009). 
Where individuals have to pay out of pocket to meet the cost of treatment, the cost can 
be as much as 25% of the monthly household income. As a result, malaria contributes 
significantly to poverty and reduced economic development in the hardest hit countries 
(World Bank, 2009).  
 
As part of efforts to respond to the increased incidence of drug resistance, novel 
compounds or new molecular entities (NMEs) are being developed to meet the 
continued need for both the treatment and prevention of malaria (MMV, 2014; 




be conducted to collect therapeutic efficacy and harms data in order to develop 
accurate risk: benefit profiles. These studies are needed to monitor for the emergence 
and spread of antimalarial drug resistance or fill gaps in knowledge about their use in 
understudied vulnerable populations that carry a high disease burden, such as pregnant 
women, young children or those with prevalent comorbidities.  
 
Harms data collection aims to assess “the totality of possible adverse consequences of 
an intervention or therapy” and safety is inferred when there is “substantive evidence 
of an absence of any harm” (Ioannidis et al, 2006). This would mean that any recorded 
“untoward or unfavourable medical or psychological occurrence in a participant, 
including any abnormal laboratory finding, symptom or disease”, otherwise known as 
an adverse effect (AE), would form the basis of such evidence of harm. An AE does 
not necessarily have a causal relationship with the intervention or any risk associated 
with the research (ICH, 1996a).  Although adverse drug reactions (ADRs) are widely 
considered to be synonymous with AEs, it is important to draw the distinction that 
ADRs are those harmful events for which there is a strong and well established causal 
link with the drug or intervention (Ioannidis et al, 2006). 
 
For the assessment of safety (absence of harm), data endpoints include both objective 
measures (such as from clinical observations and laboratory tests) and participant-
reported adverse events (AEs). These data are then assessed for potential relation to 
the study drug, which requires review of what is known about a participant's medical 
history and use of non-study medications.  
 
There is no universal questioning method for eliciting (i.e. drawing an answer out) 




may influence the AE data reported (Ioannidis et al, 2006; FDA, 1995; ICH, 1996b). 
Many clinical trials are not powered for a safety objective and, in particular, are unable 
to identify rare AEs (Seligman, 2003). In such cases, meta-analysis can be useful. This 
involves combining AE information from relevant studies, thus increasing the 
likelihood of detecting infrequent or delayed AEs which usually only occur in less than 
1 in every 1000 participants (Higgins and Green, 2011; Seligman, 2003). The use of 
AE data collected using different elicitation methods presents a challenge in that data 
may not be comparable across different studies and, as such, cannot be successfully 
pooled in meta-analysis (Higgins and Green, 2011; Seligman, 2003). 
 
Regulatory agencies such as the United States Food and Drug Administration (FDA) 
mandate that the way AEs are elicited be explicit in study reports (FDA, 1995; ICH, 
1996b). However, they do not specify a particular method and, as such, the methods 
used to collect AE and/or non-study medication data may be variable across different 
studies (Bent et al, 2006). Development of a harmonised elicitation approach, within 
a particular therapeutic area like malaria, could be one way of helping with the 
interpretation of individual study results and pooling of data from different studies.  
 
This review will summarise key literature related to this important topic and aims for 
a better understanding of the range of methods which have been used, their impact on 
data reports, and opinions about the optimal method. Included is the range of 
questioning approaches being used in general and specifically in malaria clinical 
research. Findings from research which compares AEs elicited when different question 
methods are used in clinical trials will also be described together with an overview of 




for further research. The literature review will be used to justify the need for the 
research conducted in this thesis, and inform the research methods used.  
 
The work of this Delphi is located within a broader framework of harmonised 
approaches for eliciting, assessing and recording participant-reported antimalarial 
safety data. The overall project (empirical research, survey, Cochrane review and the 
Delphi) reflects observations of how researchers in other therapeutic areas are working 
towards the same goals as regards harmonisation of methods used in recording safety 
or other health-related data (Booth et al, 2011; Basch, 2011; Woodworth et al, 2007).  
The need to investigate the impact of different elicitation methods lends itself in 
particular to a Cochrane review methodology.  Hence this literature review summarises 
the findings from a Cochrane review related to the current body of work which 
reviewed literature comparing AE elicitation methods in a systematic way. The 
Cochrane review process itself, revealed articles that did not involve a methods 
comparison and were therefore excluded, but which allowed for a description of the 
range of methods used and opinions about optimal methods. 
 
2. LITERATURE SEARCH STRATEGY  
The search strategy used for this literature review is that used in a Cochrane systematic 
review of studies comparing two or more AE elicitation methods, for which I am a co-
author1. Eligible studies could be comparisons within clinical drug trials themselves 
or experiments outside of a trial but comparing questioning methods relevant for 
clinical trials. An information professional assisted with the design and conduct of the 
search which involved the following databases: EMBASE (OVID), MEDLINE 
                                                          
1 Protocol published in the Cochrane Library (Allen et al, 2013a), the review itself is in final draft 




(OVID), MEDLINE in Process and Other Non-Indexed Citations, the Cochrane 
Methodology Register (Wiley Online), the Cochrane Central Register of Controlled 
Trials (Wiley Online), the Cochrane Database of Systematic Reviews (Wiley Online), 
the Database of Abstracts of Reviews of Effects (Wiley Online), the Health 
Technology Assessment database (Wiley Online), CINAHL (EBSCO), CAB 
Abstracts (OVID), BIOSIS (Web of Knowledge), the Science Citation Index (Web of 
Knowledge), the Social Science Citation Index (Web of Knowledge), and the 
Conference Proceedings Citation Index – Science (Web of Knowledge). The key terms 
and concepts included: [A]: Adverse events AND measurement; [B]: Participants 
AND elicitation (also other synonyms for the extraction of information about adverse 
effects from people); [C]: Participants AND checklists (also other synonyms for the 
methods used to extract information about adverse effects from people). Pragmatic 
approaches were used to limit the search results whilst trying to maintain sensitivity. 
Reference lists of those articles found through the search were also assessed manually 
to identify additional relevant studies. The results of the Cochrane search are shown in 
Figure 1. Studies excluded from the Cochrane Systematic Review that offered useful 







3. SUMMARY AND INTERPRETATION OF LITERATURE 
The detail about approaches used to elicit AE data reports from study participants is 
rarely presented in published articles of clinical research studies (Loke & Derry, 2001). 
A summary of the reference articles related to the current research are listed in Table 
1 below. 
 




3.1 Range of elicitation methods for questioning trial participants about their health 
a. General/open-
ended enquiry 
Allen et al, 2013b;  
Avery et al, 1967;  
Huskisson & Wojtulewski, 
1974;  
Torok et al, 1984;  
Bent et al, 2006;  
Barrowman et al, 1970;  
Borghi et al, 1984;  
Spilker, 1987;  
Ciccolunghi & Chaudri, 
1975;  
Brent et al, 2009;  
Downing et al, 1970;  
Hermans et al, 1994;  
Jacobson et al, 1987;  
Nicholls et al, 1980;  
O'Connell et al, 2007;  
Perez-Lopez et al, 2012;  
Rabkin et al, 1992;  
Os et al, 1994 
Reilly & Zbrozek, 1992;  
Rosenthal et al , 1996;  
Wallin & Sjovall, 1981;  
Wernicke et al, 2005;  
Landen et al, 2005;  
Yeo et al, 1991;  
Kruft et al, 2007;  
Monteiro et al, 1987;  




Allen et al, 2013b;  
Avery et al, 1967;  
Huskisson & Wojtulewski, 
1974; Torok et al, 1984;  
Bent et al, 2006;  
Barrowman et al, 1970;  
Borghi et al, 1984;  
Spilker, 1987;  
Ciccolunghi & Chaudri, 
1975; 
Brent et al, 2009;  
Downing et al, 1970;  
Hermans et al, 1994;  
 
Jacobson et al, 1987;  
Nicholls et al, 1980;  
O'Connell et al, 2007;  
Perez-Lopez et al, 2012;  
Rabkin et al, 1992;  
Reilly & Zbrozek, 1992; 
Rosenthal et al , 1996;  
Wallin & Sjovall, 1981; 
Wernicke et al, 2005;  
Landen et al, 2005;  
Yeo et al, 1991;  
Levine & Schooler, 1986 
Kruft et al, 2007;  
Monteiro et al, 1987;  
Greenhill et al, 2004;  
Os et al, 1994;  
Barber & Santanello, 
1995;  
de Vries et al, 2014;  
Sheftell 2004,  
Lundberg, 1980;  
Wallander et al, 1991;  
Wernicke et al, 2005 
c. Other 
approaches 
Barber & Santanello, 1995;  
Allen et al, 2013b;  
Kruft et al, 2007;  
Landen et al, 2005;  
Lundberg, 1980  
 
Monteiro et al, 1987;  
Os et al, 1994;  
Wallander et al, 1991;  
Yeo et al, 1991;  
 
Sheftell et al, 2004;  
de Vries et al, 2014;  









3.2 Impact of different elicitation methods on AE data collected 
a. General/open-
ended enquiry 
Barber & Santanello, 1995;  
Downing et al, 1970;  
 
Allen et al, 2013b  
Reilly & Zbrozek, 1992;  
Greenhill et al, 2004 
Jacobson et al, 1987;  





de Vries et al, 2013 
Allen et al, 2013b 
3.3 Opinions on optimal methods for eliciting AEs 
a. General/open-
ended enquiry 
Wernicke et al, 2005;  
Huskisson & Wojtulewski, 
1974; 
 





Wernicke et al, 2005   
3.4 Questioning trial participants about the use of non-study medication 
 ICH, 1996b 
Ceh, 2007 
 
3.1 Range of elicitation methods for questioning trial participants about 
their health 
There are two prominent types of elicitation methods used to ask participants about 
their health to collect AE data; general enquiries and structured questioning methods. 
The general enquiry, also known as an open-ended enquiry, spontaneous reporting or 
sometimes unsolicited reporting, involves asking participants a general question about 
their health over a particular part of the study period, such as “Have you had any 
problems or felt unusual in any way since your last visit?” (As shown in Table 1 
section 3.1 sub-section a). The structured enquiry, meanwhile, uses more specific 
questioning, typically in reference to a list of known or suspected AEs associated with 
the drug (As presented in Table 1 section 3.1 sub-section b). The structured enquiry 
may involve the use of a tool, usually in the form of a checklist or questionnaire. An 
example is the Systematic Assessment for Treatment Emergent Events (SAFTEE) 
which was developed for detecting side-effects in psychiatric clinical trials (Levine & 




eliciting AE data include the use of diaries, blank forms for participants to note their 
symptoms, rating scales and occasionally in-depth interviews (As listed in Table 1 
section 3.1 sub-section c).  
 
3.2 Impact of different elicitation methods on AE data collected 
The literature search revealed that the detection of AE data across different therapeutic 
drug categories is influenced by a number of factors, including the elicitation, or 
questioning, methods used to collect information from the trial participants about their 
health. The Cochrane review showed that in almost all comparisons, a checklist or 
rating scale for collecting AE data resulted in a higher number of AEs reported when 
compared to a general questioning method or open-ended enquiry (the latter including 
a non-structured diary or blank form to complete) (Allen, EN; personal 
communication2). The open-ended enquiry was found to yield reports of AEs which 
were more clinically significant and required modification of the clinical management 
of the trial participants in 6 studies (As shown in Table 1 section 3.2 sub-section a). 
Content validation of some structured questioning tools was found to be problematic 
and required that participants be given clear instructions on how to interpret items 
listed in the tool (de Vries et al, 2013). 
 
The impact of different types of questioning techniques was investigated qualitatively 
in one study that was relevant for malaria research (Allen et al, 2013b). Participants in 
antiretroviral/antimalarial interaction clinical trials in South Africa and Tanzania were 
questioned verbally about their AEs and non-study medication using a general enquiry 
followed by a check-list enquiry. Participants reporting differently between the two 
                                                          
2 Protocol published in the Cochrane Library (Allen et al, 2013a), the review itself is in final draft 




methods were invited to participate in an in-depth interview and focus group 
discussion to explore the reasons for the contrast in reporting between the two 
elicitation methods. The findings confirmed that in moving from the general enquiry 
to the check-list (and subsequently to in-depth interviews), there was an overall 
increase in the number of AEs reported, as reported previously. The qualitative 
component of this study revealed that differences in reporting between the two 
questioning methods related to participants' recognition of health issues, their 
perceptions of what was important or necessary to report, and what they felt 
comfortable to reveal. Specifically, the reasons for the increase in AE reporting 
included forgetting to report events when asked a general enquiry and being prompted 
by the checklist (and to a lesser extent the in-depth interview); not reporting AEs which 
participants judged to be minor, less severe or irrelevant to the study; neglecting to 
report events out of fear of negative consequences and limited knowledge and 
recognition of treatment names. The different trial contexts also played a role in that 
fear of reporting was related to concern about being withdrawn from the trial in South 
Africa compared to going against the perceived “hospital rules” (mainly about the use 
of traditional medicines) in Tanzania. 
 
3.3  Opinions on optimal methods for eliciting AEs 
Variation in AE reporting rates resulting from use of different elicitation methods date 
back more than forty-five years, but there remains no universally accepted questioning 
method or set of tools to date, even for a specific therapeutic group of compounds 
(Avery et al, 1967; Huskisson & Wojtulewski, 1974). Among researchers, there is no 
consensus on which method is the most appropriate for collecting AE data; each has 
proponents and opponents. Those who are partial to the general enquiry consider it to 




their response (Wernicke et al, 2005; Huskisson & Wojtulewski, 1974). They are 
concerned that the structured enquiry artificially increases the reporting rate as it may 
be suggestive thereby influencing participant responses (Wernicke et al, 2005; Barber 
& Santanello, 1995). Proponents of the structured enquiry argue that this method is 
more sensitive as it collects AE data which participants may not report in the 
spontaneous enquiry because they have forgotten an event, or did not associate any 
change in health with the study drug among other reasons (Wernicke et al, 2005). They 
also argue that the use of a control group could be used to mitigate the higher reporting 
rate in the solicited (structured) enquiry group (Wernicke et al, 2005).  The greatest 
challenge in using the different elicitation techniques across different clinical trials is 
that this could result in substantial disparities in the number and type of AEs reported, 
which compromises the accuracy and reliability of defining the drug’s safety (and risk 
: benefit) profile. 
 
These differing opinions were investigated in the survey of antimalarial drug 
researchers mentioned above (Allen et al, 2013c). The rationale for using 
combinations of methods or favouring one method over another included the desired 
“specificity or comprehensiveness of the data sought”, “avoidance of suggestion of a 
certain response”, the “feasibility” of using certain methods and determining the 
appropriateness of the questioning method based on their knowledge of participants’ 
“perceptions about health”. There was, however, overlap in choosing different 
questioning methods to fulfil the same rationale.  
 
3.4 Questioning trial participants about the use of non-study medication 
Although most literature related to the issue of differential questioning methods to 




study medication data can also influence the interpretation of safety and efficacy end-
points in a clinical drug trial. Prior non-study medication will influence eligibility for 
a trial while concomitant non-study medication data is important due to the potential 
for drug-drug interactions which may have direct or indirect effects on the study drug’s 
safety profile (ICH, 1996b). It is also important to know what (if any) non-study 
medications were used by trial participants to be able to consider if they caused an AE 
rather than the study drug (Ceh, 2007; ICH, 1996b). Lastly, eliciting indications for 
the use of non-study medication can also help identify unreported AEs. It is therefore 
equally important to specify how data on non-study medications will be assessed and 
recorded to avoid ambiguity and challenges in interpreting study findings at a later 
stage. Some of the methods used to collect and record information about non-study 
medication are not always accurate and unambiguous and this has the untoward effect 
of reducing the veracity of the study drug’s safety profile (Ceh, 2007). Non-study 
medication information obtained through the use of explicitly defined elicitation and 
recording methods facilitates accurately characterising AEs, conducting causality 
assessments and detecting drug interactions, all of which contribute towards defining 
a study drug’s safety profile (Ceh, 2007). 
 
The antimalarial methods' survey mentioned above (Allen et al, 2013c) investigated 
how participant-reported non-study medication use data are elicited in drug studies. 
Most researchers made use of the general enquiry when asking questions about use of 
non-study medication with explicit reference to “prescription only medication”, “over-
the-counter medication”, “traditional medication”, “supplements” and “vaccinations”. 
Researchers also incorporated pictorial questioning tools such as pictures, diagrams 
and pictorial diaries either alone or in combination with general or structured enquiry. 




structured enquiry as they could enhance understanding, particularly in low literacy 
settings (Allen et al, 2013c). Structured questions, meanwhile, were considered useful 
for revealing specific medicines such as recent prior use of antimalarials. The 
qualitative study nested within these antimalarial/antiretroviral interactions trials 
found that the number of non-study medication reported also increased as the 
elicitation methods became more detailed or intensive (Allen et al, 2013b). The 
reasons were similar as for AEs; more detail helped participants recognise what the 
investigators considered as medicines and that reporting use of these was relevant for 
the trial. 
 
4. IDENTIFICATION OF GAPS AND JUSTIFICATION FOR FURTHER 
RESEARCH 
As there is still no consensus about optimal methods for eliciting participant-reported 
AE and non-study medication data in malaria clinical studies, despite their influence 
on the data collected, there is need for further research in this area. The ideal approach 
to finding the optimal elicitation method is unclear as this is a complex field. However, 
a good approach for achieving consensus about this topic among researchers is a 
Delphi study, as it is specifically designed to solicit opinion from those with relevant 
expertise in a particular area with the aim of achieving consensus on a particular topic. 
The current research, conducted as part of the requirements for the degree Master of 
Public Health, expands on the previous work summarised above, which initiated a 
dialogue on the development of harmonised elicitation approaches for antimalarial 
clinical studies (Allen et al, 2013c). This dialogue will now be continued through the 
use of a Delphi process with antimalarial drug clinical researchers to work towards the 
design of appropriate and feasible methods or tools for detecting participant-reported 




will be achieved by working on generating consensus among a group of experienced 
and knowledgeable antimalarial drug researchers on potential methods and tools.  
 
It is particularly important to optimise methods for accurately assessing the safety of 
antimalarials because many drug regimens currently in use are relatively new and yet 
are already being deployed widely, even in vulnerable at-risk populations without 
malaria as preventive treatment or for transmission blocking (MMV, 2014; Burrows 
et al, 2014). Defining their safety profiles accurately is thus important to help to inform 
clinical practice, and could boosts efforts to enhance the acceptability of new drug 
treatments in the target populations. Harmonised elicitation methods could help with 
the interpretation of individual studies but also to enable valid pooling of AE data 
across different studies (with similar contexts), which in turn would help in identifying 
rare AEs and their risk factors.  
 
5. CONCLUSIONS 
The reviewed literature showed that the use of different elicitation methods to question 
participants about their health and use of non-study medication in clinical studies, in 
general and specifically in malaria, can influence safety outcome data. Although it is 
widely accepted that there is a need to standardise these methods across different 
studies, there is limited evidence of efforts towards developing such universal methods 
and tools. The use of standardised methods would facilitate valid pooled analysis of 
individual AE data across different studies in meta-analysis. This could ultimately lead 
to the development of more accurate and reliable drug safety profiles to inform clinical 
practice. While this issue is pertinent to any drug, there is a specific need to explore 
the optimal methods for eliciting these data in malaria clinical research given the 




blocking. The harmonisation of AE and non-study medication elicitation methods will 
enhance our ability to characterise the safety profile of the novel antimalarials that are 
urgently needed given the alarming spread of drug resistance to all currently available 
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Background: Eliciting adverse event (AE) and non-study medication reports from 
clinical research participants is integral for evaluating drug safety. However, using 
different methods to question participants yields inconsistent results, compromising 
the interpretation, comparison and pooling of data across studies. This is particularly 
important given the widespread use of antimalarials in vulnerable populations, and 
their increasing use in healthy but at-risk individuals as preventive treatment or to 
reduce malaria transmission.  
Methods: Experienced, qualified antimalarial drug clinical researchers were invited 
to participate in a Delphi process, to facilitate consensus on what panellists consider 
to be optimal (relevant, important and feasible) methods, tools, and approaches for 
detecting participant-reported AE and non-study medication data in uncomplicated 
malaria treatment studies. 
Results: Of the 72 invited, 25; 16 and 10 panellists responded to the first, second and 
third rounds of the Delphi process respectively. Overall, 68% (68/100) of all 
questioning items presented for rating achieved consensus. When asking general 
questions about health, panellists agreed to include a question/concept about any 
change in health, taking care to ensure that such questions/concepts do not imply 
causality.  Eighty-nine percent (39/44) of structured items about specific signs and 
symptoms, were rated as optimal. For non-study medications, a general question and 
most structured questioning items were considered an optimal approach. The use of 
mobile phones, patient diaries, rating scales as well as openly engaging with 
participants to discuss concerns were also considered optimal complementary data-
elicitation tools.  
Conclusions: This study succeeded in reaching consensus within a section of the 




and some structured questions for eliciting data about AEs and non-study medication 
reports. The findings suggest that one method of questioning may not be superior to 
another, or sufficient to fulfil its purpose on its own and that the use of a combination 
of methods may be optimal. The concepts and items considered found in this Delphi 
survey to be relevant, important and feasible should be further investigated for 
potential inclusion in a harmonised approach to collect participant-elicited antimalarial 
drug safety data. This, in turn, should improve understanding of antimalarial drug 
safety. 
 
Key words:  
Elicitation methods, clinical trials, safety, adverse events, non-study medication, 
Delphi. 
 






Malaria is one of the greatest public health challenges in the tropics. In 2015 the World 
Health Organisation reported an estimated 214 million malaria cases globally, with an 
estimated 438 000 malaria-related deaths [1]. The disease is most prevalent in Africa 
with pregnant women and young children, mostly under five years, being the most 
vulnerable [1]. In countries where malaria is endemic, as much as 40 % of the public 
sector expenditure for health is utilised for treatment of malaria [2]. Where individuals 
have to pay out of pocket to meet the cost of treatment, the cost can be as much as 25 
% of the monthly household income. As a result, malaria contributes significantly to 
poverty and reduced economic development in the hardest hit countries [2]. 
 
An integrated approach to controlling malaria is thus essential in stemming the tide 
and impact of this disease, incorporating prevention (including preventive 
chemotherapy) as well as prompt and effective treatment of infections with efficacious 
medicines (WHO, 2015). Efforts to control and eventually eliminate malaria have 
resulted in the widespread use of artemisinin-based combination therapies (ACTs) as 
the first line treatment for uncomplicated malaria [3, 4]. 
 
As part of efforts to eradicate malaria and stem the development of resistance to 
antimalarial treatment, novel compounds or new molecular entities (NMEs) are being 
developed to meet the continued need for both the treatment and prevention of malaria 
[5,6]. Before these can be marketed for use in the general population, they must first 
be assessed in clinical trials to establish their efficacy and safety profiles. Due to 
inherent limitations of clinical trials to fully assess safety, more studies are then 
conducted post-licensure to continue to build knowledge about adverse drug effects 




clinical trials. Pooling safety data collected during numerous clinical studies facilitates 
the more accurate definition of the nature and risk of adverse effects. In so doing, there 
is an increased likelihood of the identification of sub-populations at greater risk, and 
of detecting infrequent or delayed effects. These are usually only detected with large 
sample sizes (ordinarily >1000 study participants) and may be missed when smaller 
cohorts are used [7]. Using synthesised datasets to better define the safety of new 
antimalarial drugs and existing drugs in understudied populations is therefore 
important, especially where the harm: benefit balance may be shifted when these are 
used in asymptomatic or uninfected people to prevent malaria or reduce malaria 
transmission. 
 
Regulatory agencies require the method of collecting safety data to be explicit in study 
reports because of its potential impact on the study results, and, furthermore, that 
methods should be standardised within drug development programmes [8]. However, 
they do not in general specify which methods to use, and the word count constraints in 
publications may preclude sufficiently detailed description of these approaches and 
tools [9]. This compromises the interpretation of individual studies and subsequent 
systematic reviews or meta-analyses [7, 10].  
 
Drug safety and tolerability profiles are generated by gathering adverse event (AE) 
data which are then considered for any potential relationship to the study drug using 
what is known about a participant's medical history and use of non-study medication. 
Objective AE assessments include medical examinations and laboratory tests which 
are likely to be standardised within and between studies [11]. Studies also rely on 
subjective AE reports that are obtained directly from trial participants by asking them 




(elicitation) method on safety data is considered to be an important issue that has not 
received enough attention [12, 13]. A systematic review of studies in any therapeutic 
area that compared elicitation methods, reveals that more detailed questioning (such 
as with checklists or rating scales) increases the number of AEs reported compared to 
an open-ended or general enquiry (Protocol published in the Cochrane Library [14], 
the review itself is in final draft form). Proponents for a general enquiry believe it 
collects data which is more clinically meaningful even though it may be less sensitive 
[15]. An argument against the structured enquiry reflects concerns that it artificially 
increases the AE reporting rate as it may be suggestive, thereby biasing participant 
responses [16]. Structured methods may also be more time consuming and less feasible 
to conduct in practice. Proponents of the structured enquiry, meanwhile, argue that this 
method is necessarily more sensitive as it detects AE data which participants do not 
report spontaneously [17]. For malaria specifically, there is evidence that when 
participants forgot an event, or did not consider it significant or relevant when asked 
on general enquiry, a checklist enquiry prompted an AE report [18]. There may also 
be influence from the study context on reporting of AEs, medical history and non-
study medications that are not overcome by a tool, for instance where participants fear 
the consequences of reporting [18].  
 
A survey of antimalarial drug clinical researchers found that, for capturing AEs in 
intervention studies, most researchers used a combination of a general and structured 
enquiry (31%) or structured enquiry only (26 %) with less using a general enquiry 
alone (18 %) [18]. A minority of researchers incorporated tools involving pictures [19]. 
Most researchers in the survey use a general enquiry when asking questions about use 




medication”, “over-the-counter medication”, “traditional medication”, “supplements” 
and “vaccinations” [18]. 
 
The aim of this research is to seek consensus among a panel of antimalarial drug 
clinical researchers about which methods they consider optimal (relevant, important 
and feasible) for eliciting AE and non-study medication data from participants in 
uncomplicated malaria drug studies. This is expected to contribute to the development 
of a harmonised approach that may, in turn, facilitate more accurate interpretation or 
pooling of participant-elicited safety data from multiple studies.  
 
3. METHODS 
3.1 The Delphi 
A Delphi process was selected as its aim is to achieve consensus on a particular topic. 
This method was developed in the 1950s by the RAND Corporation and involves 
soliciting opinions from a panel of knowledgeable individuals with relevant 
experience and expertise in a particular area. Successive rounds of questioning about 
a topic are conducted after individual results from the previous round are reported back 
to the group for consideration [20]. Panellists remain anonymous to each other to avoid 
domination by any one individual and to allow for freedom of expression without 
reservation or fear of condemnation or ridicule [21, 22, 23]. Typically the length of a 
Delphi study varies from three to five rounds and is dependent on the degree of 
consensus required by the investigators and the criterion chosen to define consensus 
[22, 24]. 
 
Questionnaires (Questionnaires included as additional files under Appendix I) to elicit 




through SurveyGizmo so that panellists did not have to be in the same physical 
location, and could complete each survey at a convenient time [25,26].  
 
In the first round panellists were presented with a summary of relevant literature, and 
were asked open-ended questions about what they considered the optimal method(s), 
concept(s) and/or approach(es) for asking study participants (or caregivers) to collect 
subjective AE and non-study (previous/concomitant) medication data (Participant 
Information Sheet and Literature and Survey Results Summary included as additional 
files under Appendices II and III respectively). Space was provided for free-text 
comments and suggestions of further methods or considerations pertinent to this 
complex field.  
 
In round two, specific phrases suggested by pannelists in round one were then assessed 
in terms of their underlying meanings and categorised into questioning concepts for 
rating in subsequent rounds as regards their relevance, importance and feasibility, i.e. 
to be optimal they should fulfil all three criteria as all would be appropriate for malaria 
clinical research for detecting participant-reported AEs and non-study medication. The 
definition of consensus in Delphi process studies varies. For this study,  each 
component was considered to have reached consensus when at least 70 % of panellists 
selected options within a three-point region of a nine-point Likert scale containing the 
median indicating that most panellists disagree (score 1–3), are uncertain (score 4–6), 
or agree (score 7–9) that a given item is optimal [22, 27, 28]. Individual items were 
not mutually exclusive – for example, panellists could recommend both a general 
enquiry and a structured enquiry method. 
 




and panellists were advised that the wording of questions or items themselves were 
only examples of possible phrases/words and that exact terminology may be context-
specific or adapted for ensuring local understanding of the question by study 
participants. The intention was for participants to consider the concepts behind the 
general questions rather than evaluate the questions themselves, hence the inclusion of 
some illustrative examples. For instance, they were asked to rate the following types 
of general question concepts (with examples) that may be posed to participants in an 
antimalarial study: "General question about feeling (e.g. ‘How have you [has your 
child] been feeling?)". This approach was applied throughout the Delphi, where 
appropriate. Similarly, an example of a structured approach was "Questions about 
body parts, systems or functions (e.g. Have you experienced a problem with your head, 
chest, breathing?)". Rating was achieved using a nine-point Likert scale with options 
ranging from ‘strongly agree’ to ‘strongly disagree’. 
 
In the third and final round, each panellist was sent descriptive statistics summarising 
responses from round two and a copy of their individual responses. Items which 
achieved consensus in round two were presented in a summary at the beginning of 
round three but were not submitted for reassessment. For items that had not achieved 
consensus they were asked whether or not they wished to change their opinion/rating 
in light of the summary information from all panellists [27].   
 
 
4. STUDY POPULATION AND SAMPLING 
4.1 Population  
Participation was limited to individuals with experience and knowledge of clinical 




[21, 25]. All panellists needed to meet one or more of the following criteria: 
(i) A clinical researcher who has been responsible for a clinical trial/study where 
AE and/or non-study medication data was collected as part of the protocol. 
(ii) An individual who has been responsible for the selection, design, review or 
testing of tools to collect clinical trial/study AE and/or non-study medication 
data. 
(iii) An individual who has had direct involvement in the elicitation and recording 
of AE and non-study medication data from participants within malaria clinical 
trials/studies. 
(iv) A regulatory authority responsible for reviewing clinical trial/study data, 
whether pre- or post-marketing. 




Sampling was purposive to ensure that those who were invited met the inclusion 
criteria, and was largely from those who had taken part in a previous survey [29]. 
Individuals from organisations well known for researching or developing anti-malarial 
drugs were also approached. Self-selection by those invited ultimately determined who 
responded and participated in each of the rounds. In an effort to ensure that panellists 
who could be directly impacted by the results of the Delphi would remain objective in 
their review of other panellists’ opinions, the importance of remaining impartial and 
objective in their contributions was emphasised. 
 
4.3 Sample size 




results can still be obtained using a comparatively small group of even heterogeneous 
experts [30]. Some Delphi studies have shown results can be obtained using panels 
with as few as 5 or 6 panellists while other studies have used panels with as many as 
1 685 panellists [30]. Ultimately, the size of a Delphi panel is determined by the 
availability of panellists with the relevant qualities and expertise [31]. Considering our 
highly specific inclusion criteria and anticipated attrition at each round, there was no 
limit set to the maximum number of participants who could take part, and no sample 
size calculation was done. There was no explicit intention on a specific number for the 
minimum sample size, however the minimum sample size anticipated, based on 
Delphi-related literature, was approximately twenty panellists completing the last 
round of the Delphi [30]. 
 
4.4 Data management and analysis 
Responses were downloaded from SurveyGizmo® and analysed using Microsoft 
Excel®. The two main sections, Section A (Adverse Events) and Section B (Non-study 
Medication) were each further sub-divided to include three sub-sections on general 
questioning items, structured question items and pictorial and/or physical questioning 
tool items (Questionnaires included as additional files under Appendix I). Consensus 
was assessed individually per item included in the questionnaires, and overall per sub-
section. 
 
4.4 Ethical considerations 
Written approval to conduct the study was obtained from the Human Research Ethics 
Committee of the University of Cape Town’s Faculty of Health Sciences. The first 
page of the Delphi specified “If you would like to continue with the Delphi please enter 




continuing we will assume you have given consent to take part”. The investigators 
were blinded to each participant’s identity during data collection and analysis. Access 
to the responses was password protected and limited to members of the investigation 
team. Once the final round of the Delphi process was closed the survey was de-
activated, and links between email addresses and the website were disabled. 
 
5. RESULTS 
A total of seventy-two researchers were invited to participate, of whom 25 (35%) 
completed round one. In round two all panellists who had completed round one were 
re-invited. Of these, 16/25 (64%) responded, with fifteen fully completing the round 
and one panellist partially completing the questionnaire. In the final round all who had 
fully completed round two were invited and 10/15 (67%) responded.  
 
5.1 Study participants 
The study population was comprised mostly of panellists who met at least two of the 
inclusion criteria. Of the 25 participants in round one, 18/25 (72%) had been 
responsible for the selection, design, review and/or testing of tools, 16/25 (64 %) had 
five or more years of experience in malaria clinical studies and a further 3/25 (12%) 
had 1 - 5 years of experience. 
 
Panellists came from seventeen countries, with over half (14/25) coming from malaria 
endemic countries. Most countries represented had one panellist [Australia, 
Bangladesh, Burkina Faso, Denmark, Gabon, Gambia, Kenya, Malawi, Mali, Nigeria, 
Tanzania, Uganda, the United Kingdom] but some had more than one [United States 





5.2 Assessment of consensus  
The percentage of all items reaching consensus overall rose from 24 % in round two 
to 68 % in round 3 (Table 2). The majority of items reaching consensus in round two 
were structured questions about signs and symptoms and non-study medication. 
 
Table 2 Overall number of questions reaching consensus by sub-section 
Elicitation methods Number 
of items 
Items reaching Consensus  
Adverse events Round 2 Round 3 Total 
General questions  5 1 1 2 (40%) 
Structured questions about body 
parts, systems or function 
11 0 3 3 (27%) 
Structured questions about signs 
and symptoms 
44 16 24 40 (91%)  
Pictorial questioning tools  14 0 2 2 (14%) 
Other  8 1 4 5 (63%) 
Non-study medication     
General questions  1 1 N/A 1 (100%) 
Structured questions  11 5 5 10 (91%) 
Pictorial and/or other physical 
tools  
5 0 4 4 (80%) 
Other 1 0 1 1 (100%) 
Total 100 24 44 68 (68%) 
 
5.3 Asking participants about AEs  
Panellists agreed that an explicit question about change in health (e.g. 'Have you 
observed any change or new complaint since your last visit/ in the past x days [trial-
specific time scale]?') was optimal for asking about AEs during malaria clinical trials. 
They also agreed that a general question implying causality should be avoided (e.g. 
'Did your child experience any side effect from the drug since your last visit/ in the 




pertaining to the general questions asking about how a study participant was feeling 
(e.g. 'How have you [has your child] been feeling since your last visit/ in the past x 
days [trial-specific time scale]?), whether they had had past adverse reactions to 
treatments (e.g. 'Have you ever reacted badly to a drug or vaccine') or how they rated 





Table 3 Summary of consensus status for individual questioning items*  
ITEMS RATED FOR RELEVANCE, IMPORTANCE AND FEASIBILITY CONSENSUS STATUS 
SECTION A:    
GENERAL QUESTIONS ABOUT AEs Round 2 Round 3 
Explicit question about change in health (e.g. 'Have you observed any change or new complaint since your 
last visit/ in the past x days [trial-specific time scale]?') 
Include  
Question implying causality (e.g. 'Did your child experience any side effect from the drug since your last 
visit/ in the past x days [trial-specific time scale]?') 
 Exclude 
General question about feeling (e.g. 'How have you [has your child] been feeling since your last visit/ in the 
past x days [trial-specific time scale]?) 
 No consensus 
 
General question about past adverse reactions to treatments (e.g. 'Have you ever reacted badly to a drug or 
vaccine').  
 No consensus 
General question about rating any change in health (e.g. 'How do you rate your state of health after taking the 
study medicine?'). 
 No consensus 
STRUCTURED QUESTIONS ABOUT BODY PARTS, SYSTEMS OR FUNCTION  Round 2 Round 3 
Nose  Include 
Lungs/breathing  Include 
Head   Include 
Ears  No consensus 
Throat  No consensus 
Eyes  No consensus 
Chest  No consensus 




STRUCTURED QUESTIONS ABOUT BODY PARTS, SYSTEMS OR FUNCTION (CONT.)  Round 2 Round 3 
Nervous system   No consensus 
STRUCTURED QUESTIONS ABOUT SIGNS AND SYMPTOMS Round 2 Round 3 
Tiredness/ fatigue/ weakness/ lethargy  Include 
Muscle pain  Include 
Joint pain  Include 
Abdominal pain  Include 
Mood/ behavioural change  Include 
Allergic skin rash (e.g. some forms of urticaria)  Include 
Skin abnormalities   Include 
Dizziness  Include 
Vision/sight problem  Include 
Change in urine colour  Include 
Palpitations  Include 
Confusion  Include 
Jaundice/icterus  Include 
Oculogyric crisis  Exclude 
Photosensitivity (sensitivity to light)  Include 
Spontaneous bleeding  Include 
Constipation  Include 
Blisters (on skin or mucous membrane)  Include 
Hallucinations  Include 
Headache Include  
Fever Include  




STRUCTURED QUESTIONS ABOUT SIGNS AND SYMPTOMS (CONT.) Round 2 Round 3 
Loss of appetite Include  
Vomiting Include  
Nausea Include  
Diarrhoea Include  
Itching (no rash) Include  
Peeling skin Include  
Tinnitus (ringing in the ears)/ hearing problem Include  
Sleep disturbance/ nightmares Include  
Involuntary movements (e.g. rigors/ convulsions/ seizures) Include  
Wheezing/ difficulty breathing Include  
Non-allergic skin rash (e.g. scabies)  No consensus 
Posturing  No consensus 
Pallor  No consensus 
Change in walking (gait disturbance)  No consensus 
In infants:   
Eating/drinking/ feeding less than normal  Include  
Irritable   Include 
Abnormal sucking, if breastfed   Include 
Crying more than normal  Include 
Difficult to arouse  Include  
In pregnant women:   
Baby movements less than normal   Include 
Vaginal bleeding   Include 




PICTORIAL QUESTIONING TOOLS ABOUT AEs  Round 2 Round 3 
Using photographs, drawings or pictures of the following signs and symptoms:   
Mucous membrane blisters  Include 
Skin rash  Include 
Headache  No consensus 
Fever  No consensus 
Loss of appetite  No consensus 
Diarrhoea  No consensus 
Jaundice/icterus  No consensus 
Joint pain  No consensus 
Pruritus  No consensus 
Using photographs, drawings or pictures of the following body parts:   
Respiratory system  No consensus 
Gastrointestinal tract  No consensus 
Central nervous system  No consensus 
Skin  No consensus 





OTHER  Round 2 Round 3 
Collecting AE reports using mobile phones  Include 
Collecting AE reports using patient diaries  Include 
Using an archive of visual analogue scales from day 0 throughout all the follow-ups to measure potential AEs 
and any change in the occurrence of these events. 
 Include 
Openly engaging participants to discuss any concerns they have  Include 
Keeping an archive of digital photographs of AEs Include  
Collecting AE reports using group discussions  No consensus 
Using flip charts, with a picture on one side for the participant and a written question for the investigator on 
the reverse side (to reduce investigator variability). 
 No consensus 
Using video footage on smartphones or tablets to show how some AEs which are difficult to depict on still 
images may manifest e.g. seizure activity. 
 No consensus 
SECTION B   
GENERAL QUESTIONS ABOUT PREVIOUS OR CONCOMITANT MEDICATION (NON-STUDY 
DRUG) 
Round 2 Round 3 
General questions about the use of non-study medications (e.g. 'Have you taken any medications since your 
last visit/ in the past x days [trial-specific time scale]?'). 
Include  
STRUCTURED QUESTIONS ABOUT PREVIOUS OR CONCOMITANT MEDICATION (NON-
STUDY DRUG) 
Round 2 Round 3 
Questions about the source of medicines:   
Medicine obtained from another health facility Include  
Medicine obtained from a drug shop, pharmacy, chemical seller, the market (or equivalent) Include  




STRUCTURED QUESTIONS ABOUT PREVIOUS OR CONCOMITANT MEDICATION (NON-
STUDY DRUG) (CONT.) 
Round 2 Round 3 
Medicines already available in the home (from previous treatment courses). Include  
Medicines obtained from family and/or friends  Include 
Collecting and using naturally occurring herbs/remedies Include  
Structured questions about treatment class or specified indication:   
Analgesics/ anti-inflammatory drug  Include 
Antibiotics  Include 
Antihistamines  Include 
Antimalarial  Include 
Vitamins  No consensus 
OTHER Round 2 Round 3 
Please rate the following statement to reflect the extent to which you feel it is relevant and important and 
feasible for collecting non-study medication data. "Participants should be asked about individual treatments 
by name according to what is known to be locally relevant?"  
 Include 
PICTORIAL AND/OR OTHER PHYSICAL TOOLS TO QUESTION ABOUT PREVIOUS OR 
CONCOMITANT MEDICATION (NON-STUDY DRUG) 
Round 2 Round 3 
 
Showing photographs or drawings of commonly used drugs or drug packets  Include 
Showing samples of commonly used drugs or drug packets  Include 
Showing photographs or drawings of commonly used herbs/traditional remedies  Include 
Asking participants to bring any non-study medication they may have taken before and/or during the 
trial/study to scheduled visits for a physical inspection 
 Include 
Showing samples of commonly used herbs/ traditional remedies  No consensus 
* Summary of consensus status for individual questioning items rated for relevance, importance and feasibility for asking participants in 




Few specific questions about body parts, systems or functions achieved consensus 
about whether or not they should be included in structured questioning (3 of 11 
possible items) (Table 3). However, 90 percent (40/44) of specific signs and symptoms 
achieved consensus; 39/40 of these were rated as being optimal for inclusion with one 
(oculogyric crisis) recommended for exclusion (Table 3).  
 
Consensus was also reached for showing study participants pictures or photos of 
‘mucous membrane blisters’ and ‘skin rash’ to elicit reports, with no other body parts 
being recommended for inclusion in this format. Panellists also agreed that collecting 
AE reports using mobile phones or patient diaries, using an archive of visual analogue 
scales or digital photographs of AEs and “openly engaging participants to discuss any 
concerns they have” were all ideas that should be considered (Table ). 
 
5.4 Asking participants about non-study medication use  
Panellists agreed that asking a general question about the use of non-study medications 
(e.g. 'Have you taken any medications since your last visit/ in the past x days [trial-
specific time scale]?') was optimal, as were, in addition, all but one of the eleven 
structured questioning items on source of medicines, treatment class or specified 
indications (Table ). The one item which failed to achieve consensus was whether or 
not items about “vitamins” as a treatment class were optimal. Panellists could also not 
agree whether to include or exclude the option of showing samples of commonly used 
herbs or traditional remedies specific to the study context. However, they did agree 
that participants should be asked about individual treatments by name according to 







This study builds on previous work aimed at working towards the development of 
harmonised tools for asking antimalarial clinical research participants about any 
potential adverse events and use of non-study medication. The results suggest that a 
combination of questioning methods is considered optimal for enhancing the reporting 
of these data in uncomplicated malaria treatment studies. The specific items which 
achieved consensus may be considered for inclusion in the development of harmonised 
approaches for data collection. Some items that did not achieve consensus for use 
could still be useful in some contexts and as such should rather be considered on a 
study by study basis. 
 
Consensus was achieved among panellists that, when asking general questions to 
capture subjective AE reports, it should be clear that the enquiry is about a change in 
health but does not imply that participants consider the study drug as the cause of the 
change. These concepts, when carefully phrased, are likely to allow participants to 
report any new medical occurrence without suggesting that he/she try to associate their 
experience with the study drug. This would be consistent with a tenet of assessing drug 
safety, capturing AEs regardless of whether or not they are thought to be attributed to 
the drug [32]. While investigators have been aware of this for decades, it is important 
to be careful about phrasing an open question about health to help ensure that study 
participants do not unwittingly filter information during reporting. To overcome this, 
some teams ask staff to use a standard phrase [29]. The concept of an ideal phrase for 
general questions postulated through this Delphi study should prove useful to guide 
trial teams in designing their AE elicitation methods, and could be used to achieve 
consistency within and between trials. Alternatively, should staff be allowed to 




and potential implications of subtle changes in wording. Open engagement with 
participants to discuss any concerns they may have was also considered useful by the 
panellists to help overcome any preconceptions about the negative consequences of 
reporting. When designing and implementing question approaches there should be 
cognisance of the literature relating to health communications, and work already 
conducted with clinical research staff who question malaria patients about AEs 
[19,33,34]. 
 
In recent work focused on antimlarial research, investigators were able to develop 
novel questioning tools and processes which could be accurately administered by non-
clinicians. In particular, there was a focus on encouraging free sharing of information 
between the participant/patient and investigator/reporter by increasing trust and 
consensus in the process, in addition to encouraging equal responsibility between the 
two parties in reporting AEs [19]. Other work in the health communications field 
implores professionals to remain cognisant of the variety of lay people's definitions of 
drugs/medicines and this would include a consideration of the potential impact of any 
discrepancies of AE reporting [35]. 
 
There was also agreement, however, between the Delphi panellists about optimal 
structured questions to elicit AE reports, presenting various signs and symptoms for 
participants to consider. General and structured questions are therefore not necessarily 
mutually exclusive. As shown by previous studies, a structured approach is likely to 
increase the sensitivity of detecting AEs, some of which may have been forgotten or 
not considered relevant or important by participants [13, 18]. While this may increase 
the workload for trial staff, using a list will ensure standard practice within and 




was overlap between some items identified as optimal (e.g. several skin conditions 
were considered for inclusion in a questioning tool individually and also as a general 
term). Panellists also suggested using digital photos of AEs (e.g. of ‘mucous 
membrane blisters’), to complement the lists.  
 
A higher degree of consensus was achieved with the questioning sub-section 
pertaining to eliciting non-study medication reports compared to AE reports. It may 
be that there is less controversy about whether different questioning methods impact 
on the data for non-study medication exposures than AEs, with a smaller potential for 
these questions biasing responses. The data are inherently different - AEs being more 
subjective experiences, while taking a non-study medication being a more concrete 
occurrence. However, from a study participant's perspective, there may be different 
perceptions of what constitutes a medicine, so giving definitions and examples can 
avoid misunderstandings [35]. Consistent with the findings relating to AE reports, 
panellists also agreed that non-study medication data should be elicited using general 
questions. Structured questioning tools could however be used in conjunction with 
general questioning items to ensure that trial participants do not inadvertently omit 
information about their use of medication (particularly over the counter, traditional, 
alternative or complementary medicines) based on their own understanding of what 
constitutes a medicine. As it is unlikely to be feasible to have an exhaustive list of 
medicines, combining a general and more specific question will allow for capturing 
items not mentioned on a list. As for AEs, the details of optimal permutations that 
should be used when developing a harmonised approach were not resolved during the 





In relation to non-study medication use data, consensus was reached that participants 
in clinical trials should be asked about individual treatments by name (and treatment 
class) according to what is relevant in the local context. In some instances the 
indication for which the non-study medication was taken could identify an unreported 
AE which may have resulted from taking the study medication [36]. All the proposed 
questioning items pertaining to the source of medication (for example a health facility, 
traditional healer; chemical seller, family and/or friends) achieved consensus. Asking 
about the source of medicines may alert the researcher of what participants consider 
to be medicine, and vice versa, and this could be particularly important in communities 
where the use of alternative and/or traditional medicines or remedies is widespread 
and common practice. In some contexts, there may be reluctance to volunteer some 
information, such as traditional therapies. There should be discussion within the team, 
therefore, as to how to encourage participants to feel comfortable enough to report 
those items without fear of negative consequences, such as being admonished by 
investigators for using such non-study medication. However, in some clinical trials 
admitting their use could result in their being ineligible for inclusion, when it would 
important to compensate participants for their time thus far and ensure prompt 
effective case management either by the study team or nearby health facility. If 
participants are already enrolled in a study, eliciting all non-study medication data is 
essential for assessing causality and describing the safety and tolerability profile of the 
study drug(s). Thus it is preferable to retain the participant in the intention to treat 
population rather than withdraw the participant, unless this is would put the participant 
at increased risk. 
 
The findings suggest that one method of questioning may not be superior to another, 




and use of non-study medication. It is therefore likely that a combination of 
questioning methods, augmented by openly engaging with participants to ensure they 
feel open to share their experiences without fear of reprimand, may be the optimal 
approach in malaria clinical research. Thus, the details of optimal permutations not 
resolved during the Delphi and refinement of this basket of potential options, should 
now be taken forward for further discussions within the anti-malarial drug research 
community. This could be done at the time of international meetings with those 
interested malaria researchers, ideally joined by health communications specialists and 
those who have experienced malaria as a patient. 
 
7. LIMITATIONS 
Due to respondent fatigue and time constraints the Delphi was terminated before 
consensus on all items could be established. While consensus for those unresolved 
items may have been achieved in further rounds, this is not necessarily the case. The 
lack of consensus on these items indicate that those items are not widely considered 
optimal. This may reflect the complexity of the topic, which is likely further 
confounded by the differing contexts in which the panellists conduct research. The 
time lapse between rounds of the Delphi ranged between three to six months. This may 
have contributed to the attrition rates between rounds and may have reduced the quality 
of responses. The length and complexity of the survey, including the composite 
concept used for the definition of 'optimal', may have further contributed to the attrition 
between rounds. Arguably ‘importance’ and ‘feasibility’ are different notions and 
participants may have felt it difficult to try and consider them together. The panellists 
who completed all three rounds were similar in their background and experience, 
which may have biased the findings towards the opinions of a select few. During round 




rounds. This indicated that there may have been some misunderstanding of the concept 
of “participant-reported” AEs. 
 
8. RECOMMENDATIONS 
This online Delphi process showed that it is possible to engage multiple antimalarial 
researchers from around the world to collaborate on working towards the development 
of harmonised approaches for questioning participants about AE and non-study 
medication data. The results should now be taken forward for further refinement and 
pilot testing of harmonised tools. These will require deliberation about optimal 
permutations of items and the potential use of mobile phones, diaries and rating scales.  
 
9. CONCLUSION 
The development of an accurate understanding of a drug's safety profile is essential 
for all medicines, especially for the antimalarials which are distributed widely to 
vulnerable at-risk populations, including uninfected persons as part of prevention 
strategies. The participant-reported data that contribute to drug safety assessments can 
be influenced by the elicitation methods used to collect this information. A harmonised 
approach for collecting AE and non-study medication data during uncomplicated 
malaria clinical studies could contribute to improving the interpretation, comparison 
and pooling of data from different studies. Such a harmonised approach could 
incorporate items that achieved consensus within this Delphi process for inclusion. For 
eliciting AEs these included: a general question concept, structured questions about 
certain symptoms, use of mobile phones, diaries, visual analogue scales and 
photographs of symptoms, and openly engaging with participants. For eliciting non-
study medication reports, these include: a general question concept; structured 




local treatments by name; showing photographs, drawings or samples of commonly 
used treatments, and asking participants to bring non-study medication to visits. One 
method of questioning may not be superior to another, or sufficient to fulfil its purpose 
on its own. As such, the results from this Delphi process suggest that combining 
questioning methods is optimal.  
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Round One Questionnaire 
Working towards consensus on methods used to elicit, assess and record 
participant-reported adverse events data in uncomplicated malaria clinical drug 
trials/studies: A Delphi Process 
 
We are interested in harmonising how uncomplicated malaria clinical research 
participants (or their caregivers) are asked about health and treatment-taking to collect 
the following types of data: medical history, adverse events and previous or 
concomitant medications. This interest is driven by the fact that interpreting or 
synthesizing results is complicated if studies use different methods for ascertaining 
and assessing these data. 
 
When answering the questions that follow please draw on your knowledge, 
experiences and opinions as well as the literature provided. Please be as candid as 











* The ACT Consortium is a group of researchers conducting projects relating to the implementation of 
Artemisinin-based combination therapies (ACT) for malaria treatment within Africa and Asia 
(www.actconsortium.org). This project is funded through a grant from the Bill & Melinda Gates 
Foundation to the London School of Hygiene & Tropical Medicine. 
 
Ethical approval for this study was granted by the University of Cape Town Research Ethics Committee. 
If you have any concerns regarding your rights and welfare as they relate to this study you can contact 
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What will being part of this Delphi require from you? 
The aim of a Delphi process is to achieve consensus about a topic. In the first round 
we will present an overview of the methods used generally in clinical research, and 
more specifically in malaria clinical drug studies, to detect, assess and record 
participant-reported data used for assessing harms (adverse events and 
previous/concomitant medications). We will then ask participants to recommend any 
additional approaches to obtain these data (this may involve a repeat of some of our 
survey questions to ensure we capture all the relevant data, including information from 
Delphi panellists who did not take part in the survey).  
 
In the second round you will be asked to rank the methods/approaches in terms of their 
relevance, importance and feasibility in uncomplicated malaria drug studies. In 
subsequent rounds we will send you a summary of the group's rankings, and where 
your own rankings fall. You will then be able to maintain your rankings or amend 
them. By the final round we hope to reach consensus between the panellists about 
which approaches, if any, are suitable for taking forward for testing and possible 
harmonisation within malaria clinical studies. 
 
As a participant you may benefit from discussion with other malaria researchers with 
considerable experience and expertise in this field of research. A disadvantage is that 
a Delphi process can be time consuming and requires commitment to complete all 
rounds. We have, however, kept our questions as brief as possible while still ensuring 
richness of the data collected. It should take between 15 - 20 minutes to complete each 
round of the Delphi. 
 
Once enrolled in the Delphi your identity will be concealed from other panellists and 
the study investigators (a research assistant not otherwise involved will manage 
communications). After the Delphi you are free to reveal your identity if you desire. 
We ask that you complete each round of the Delphi within two weeks of receiving the 
initial invitation. We strongly encourage you to complete all stages to add to the 
richness of the data collected and rigour of the study. If, however, you decide you no 
longer want to participate for any reason, you are free to withdraw at any point. 
 
If you have not read the literature review yet you can do so by clicking the link below.  
Read literature review (URL link) 




If you have any queries please contact the study investigators Nyaradzo Mandimika 
(dzadz81@gmail.com) or Elizabeth Allen (elizabeth.allen@uct.ac.za).  
 
If you would like to continue with the Delphi please enter your email address below 
and continue on to the next page. Please note that by continuing we will assume you 
have given consent to take part.  
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Section A:   How to ask participants about their health to collect adverse event 
data  
 
Through our previous survey we found that the following general question concepts 
are used to ask participants (or their caregivers) about their health to collect adverse 
events data: 
 General question about feeling.  
(e.g. 'How have you [has your child] been feeling?’)     
 Explicit question about change in health.  
(e.g. 'Have you observed any change or new complaint since your last visit?')  
 Question implying causality. 
(e.g. 'Did your child experience any side effects from the malaria treatment?') 
 
2. Are there any other general question concepts that you consider as important and 
feasible for asking participants (or their caregivers) about health to collect adverse 
event data?  
 
 Not applicable, I do not recommend general questions at all.  
 No other general question concepts considered important.  
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Section A:   How to ask participants about their health to collect adverse event data  
 
In our previous survey people said that they use the following types of structured 
questions which offer participants (or their caregivers) options to pick from when 
asking about their health to collect adverse event data:  
 Structured questions about malaria or non-malaria signs or symptoms, 
including possible expected adverse drug reactions. 
(e.g. 'Have you experienced fever, headache, skin rash?' etc.) 
 Structured questions about body parts, systems or functions.  
(e.g. 'Have you experienced a problem with your head, chest, heart, breathing?' 
etc.)  
 
For structured questions, the tools shared with us by survey participants include the 
following items: 
 
Signs or symptoms (including possible adverse drug reactions): 
Headache Tinnitus 
Fever Hearing problem 
Skin rash Vision/sight problem 
Pruritus Palpitation 
Cough Change in urine colour 
Anorexia Fatigue 
Muscle pain Confusion 
Weakness/Lethargy Numbness 
Vomiting Sleep disturbance 
Loss of appetite Nightmares 
Dizziness Infants: 
Behavioural change Crying more than usual 
Joint pain Abnormal sucking 
Abdominal pain Pregnant women: 
Allergic skin rash Baby movements less than normal 
Non-allergic skin rash Contractions more than usual 
Itching (no rash)  Vaginal bleeding 
Diarrhoea  
 







3. Are there any other structured question items that you consider as important and 
feasible for asking participants (or their caregivers) about health to collect adverse 
event data?  
 
 Not applicable, I do not recommend structured questions at all.  
 No other structured question considered important.  
 Additional signs or symptoms. (Please describe additional signs or symptoms) 
 Additional body parts, systems or functions.  (Please describe body parts, 
systems or functions) 
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Section A:   How to ask participants about their health to collect adverse event 
data  
 
Through our previous survey we found that questions aided by the use of pictures or 
pictorial diaries are used to ask participants (or their caregivers) about their health to 
collect adverse events data.  
 
For example:  
 Drawing of a body outline for participants to consider.  
 Photograph of a rash.  
 
4. Please provide us with specific details of the items that you recommend should be 
included on pictorial questioning tools or diaries about health, for example drawing of 
a body outline for participants to consider, photograph of a rash etc. (Please be as 
exhaustive as possible).   
 
 Not applicable, I do not recommend the use of pictorial question tools at all.  
 No other pictorial question tools considered important.  
 Photograph, drawing or picture of signs and symptoms, body parts or whole 
body outline. (Please describe the photograph, drawing or picture and/or 
upload an example). 
 
 
Section B:   How to ask about previous or concomitant medication 
 
In our previous survey we found that the following types of general question concepts 
are used to ask participants about their use of non-study medications to collect previous 
or concomitant medication data: 
 
General questions about the use of medications.  
 
For example: 
 ‘Have you taken any medications in the past 2 weeks/since the last visit?’  
 
5. Are there any other general question concepts that you consider as important and 
feasible for asking participants (or their caregivers) about non-study medications to 
collect previous or concomitant medication data? 
 Not applicable, I do not recommend general questions at all.  
 No other general questions considered important.  
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Section B:   How to ask about previous or concomitant medication 
 
In our previous survey we found that the following types of structured questions are 
used to ask participants about their use of non-study medications to collect previous or 
concomitant medication data: 
 

























6. Are there any other structured question items that you consider as important and 
feasible for asking participants (or their caregivers) about non-study treatments?  
  
 Not applicable, I do not recommend structured questions at all. 
 No other structured question items considered important. 
 Additional sources of medicines. (Please state additional sources of 
medicines). 
 Additional treatment classes/ specific indication. (Please state additional 
treatment classes/ specific indication). 
 Additional treatment name. (Please state additional treatment name). 
Section B:   How to ask about previous or concomitant medication 
 
Through our previous survey we found that pictorial question tools are used to ask 
participants about their use of non-study medications to collect previous or 
concomitant medication data. Examples of these tools include: 
 
 Photographs or drawings of drugs or drug packets 
 Pictures of traditional medicines 
 Pictures of mosquitoes 
 Samples of commonly used drug packets  
 
7. Please provide us with details of the items that you recommend should be included 
in pictorial question tools or used as examples.  
 
 Not applicable, I do not recommend the use of pictorial question tools at all. 
 No other pictorial question tools considered important. 
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 Photographs, drawings or pictures (Please describe the photograph, drawing or 
picture and/or upload an example). 
 
 
Section B:   How to ask about previous or concomitant medication 
 
Apart from general, structured or pictorial question methods, are there any other 
questioning methods or approaches that you consider as important and feasible for 
asking participants (or their caregivers) about use of non-study medications to collect 
previous or concomitant medication data? 
 
 Yes (If yes, please describe). 
 No  
 
 
Section C:   Other approaches to ensure accurate health and non-study 
medication reports from participants 
 
 Please consider the following approaches that may be beneficial in ensuring accurate 
reports: 
 
A phrase aimed at overcoming potential barriers to reporting about health or use of 
non-study medications. 
 
For example:  
 'I am interested to hear about everything even if you think it is not 
important.' 
 'Do not worry about telling me about something (like using herbs), you 
will not get into trouble.' 
 
Guidance for trial staff in managing communications through another person. 
 
For example: 
 Training in when and how to include children in discussions about 
their health when a caregiver is present. 
 Training in how to manage conversations through a translator.  
 
8. Are there any other questioning approaches (other than those mentioned above) that 
you consider as important and feasible for asking participants (or their caregivers) 
about their health or use of non-study medications?  
 
 Yes (If yes, please describe). 
 No  
 
Thank you! 
Thank you for taking the time to participate in this Delphi process. We appreciate your 
insights into this important and complex topic. For more information on this project, 
or if you are interested in collaborating with our research team, please contact Liz 
Allen at the University of Cape Town, South Africa (elizabeth.allen@uct.ac.za) or 
Nyari Mandimika (dzadz81@gmail.com).
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Round Two Questionnaire 
 
Working towards consensus on methods used to elicit, assess and record 
participant-reported adverse events data in uncomplicated malaria clinical drug 
trials/studies: A Delphi Process. 
 
Thank you for completing round one of the Delphi process. We would now like to 
invite you to complete the second round. 
 
In round one you and twenty-five others taking part were asked about different ways 
to question participants (or their caregivers) in uncomplicated antimalarial treatment 
studies in order to collect adverse event and non-study drug use data. We now present 
you with the collated suggestions from round one so that you can rate each type of 
question in terms of its relevance, importance and feasibility. The aim of this Delphi 
process is to achieve consensus on a 'menu' of harmonized or standard types of core 
questions to be used in a variety of uncomplicated antimalarial treatment studies. 
 
Please keep in mind the focus of this Delphi process is safety (not efficacy), and in 
particular participants' subjective responses to questions about adverse events and 
concomitant (non-study drug) medicines. The Delphi does not consider how severity 
or causality of adverse events are assessed, though this may be considered in future 
work. 
 
The different types of questioning methods need not be mutually exclusive so you can 
recommend more than one type. In future we will ask about preferred combinations 
for a global harmonized set of tools for eliciting adverse event (AE) and concomitant 
medication data. 
 
We would like to encourage you once again to complete this round of the Delphi to 
ensure the rigour of the study findings. 
   
* The ACT Consortium is a group of researchers conducting projects relating to the implementation of 
Artemisinin-based combination therapies (ACT) for malaria treatment within Africa and Asia 
(www.actconsortium.org). This project is funded through a grant from the Bill & Melinda Gates 
Foundation to the London School of Hygiene & Tropical Medicine.  
Ethical approval for this study was granted by the University of Cape Town Research Ethics Committee. 
If you have any concerns regarding your rights and welfare as they relate to this study you can contact 
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Section A:  Asking participants about adverse events (AEs) in uncomplicated 
malaria treatment studies 
   
Please rate the following types of GENERAL QUESTIONS to reflect to what extent 
you agree or disagree that each item is relevant and important and feasible for detecting 
participant-reported AE data.  
  
Please note that the questions below are only examples of possible phrases, exact 
terminology may be context-specific. 
 
Please use the rating scale below in your assessment. 
 
1 = strongly disagree, 5 = neutral, 9 = strongly agree.  
 
2. General question about feeling (e.g. ‘How have you [has your child] been feeling 
since your last visit/ in the past x days [trial-specific time scale]?’) 
1 2 3 4 5 6 7 8 9 
  
3. Explicit question about change in health (e.g. 'Have you observed any change or 
new complaint since your last visit/ in the past x days [trial-specific time scale]?')   
1 2 3 4 5 6 7 8 9 
 
4. Question implying causality (e.g. 'Did your child experience any side effect from the 
drug since your last visit/ in the past x days [trial-specific time scale]?')   
1 2 3 4 5 6 7 8 9 
 
5. General question about past adverse reactions to treatments (e.g. 'Have you ever 
reacted badly to a drug or vaccine').  
1 2 3 4 5 6 7 8 9 
  
 6. General question about rating any change in health (e.g. 'How do you rate your state 
of health after taking the study medicine?').  
1 2 3 4 5 6 7 8 9 
 
Please rate the following types of STRUCTURED QUESTIONS to reflect to what 
extent you agree or disagree that each item is relevant and important and feasible for 
detecting participant-reported AE data.  
  
Please note that the questions below are only examples of possible phrases, exact 
terminology may be context-specific. 
 
Please use the rating scale below in your assessment. 
 
1 = strongly disagree, 5 = neutral, 9 = strongly agree. 
 
Questions about body parts, systems or functions (e.g. 'Have you experienced a 
problem with your head, chest, heart, breathing?' etc.):  
 
7. Ears  
1 2 3 4 5 6 7 8 9 
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8. Nose  
1 2 3 4 5 6 7 8 9 
 
9. Throat  
1 2 3 4 5 6 7 8 9 
 
10. Eyes  
1 2 3 4 5 6 7 8 9 
 
11. Head  
1 2 3 4 5 6 7 8 9 
 
12. Chest  
1 2 3 4 5 6 7 8 9 
 
 
13. Endocrine system (e.g. diabetes, thyroid)  
1 2 3 4 5 6 7 8 9 
 
14. Heart  
1 2 3 4 5 6 7 8 9 
 
15. Lungs/Breathing  
1 2 3 4 5 6 7 8 9 
 
16. Lymphatic system  
1 2 3 4 5 6 7 8 9 
 
17. Nervous system (e.g. seizures, migraines)  
1 2 3 4 5 6 7 8 9 
  
  
 Structured questions about signs or symptoms, including possible expected 
adverse drug reactions (e.g. 'Have you experienced fever, headache, skin rash 
etc.?'). 
 
Some of these may be listed several times in different ways [e.g. different types of skin 
rash plus a summary question about skin problems]. You can indicate your preference 
through your rating score for each one. 
  
18. Headaches  
1 2 3 4 5 6 7 8 9 
 
19. Fever  
1 2 3 4 5 6 7 8 9 
  
20. Cough  
1 2 3 4 5 6 7 8 9 
 
21. Tiredness/ fatigue/ weakness/ lethargy  
1 2 3 4 5 6 7 8 9 
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22. Muscle pain  
1 2 3 4 5 6 7 8 9 
 
23. Joint pain  
1 2 3 4 5 6 7 8 9 
 
24. Abdominal pain  
1 2 3 4 5 6 7 8 9 
 
25. Loss of appetite  
1 2 3 4 5 6 7 8 9 
 
26. Vomiting  
1 2 3 4 5 6 7 8 9 
27. Nausea  
1 2 3 4 5 6 7 8 9 
 
28. Diarrhoea  
1 2 3 4 5 6 7 8 9 
 
29. Mood/ behavioural change  
1 2 3 4 5 6 7 8 9 
 
30. Skin rash  
1 2 3 4 5 6 7 8 9 
 
31. Non-allergic skin rash (e.g. scabies)  
1 2 3 4 5 6 7 8 9 
 
32. Allergic skin rash (e.g. some forms of urticaria)  
1 2 3 4 5 6 7 8 9 
 
33. Itching (no rash)  
1 2 3 4 5 6 7 8 9 
 
34. Peeling skin  
1 2 3 4 5 6 7 8 9 
 
35. Skin abnormalities  
1 2 3 4 5 6 7 8 9 
  
36. Dizziness  
1 2 3 4 5 6 7 8 9 
 
37. Tinnitus (ringing in the ears)/ hearing problem  
1 2 3 4 5 6 7 8 9 
 
38. Vision/sight problem  
1 2 3 4 5 6 7 8 9 
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39. Change in urine colour  
1 2 3 4 5 6 7 8 9 
 
40. Palpitations  
1 2 3 4 5 6 7 8 9 
 
41. Confusion  
1 2 3 4 5 6 7 8 9 
 
42. Sleep disturbance/ nightmares  
1 2 3 4 5 6 7 8 9 
 
43. Jaundice/icterus  
1 2 3 4 5 6 7 8 9 
 
44. Oculogyric crisis  
1 2 3 4 5 6 7 8 9 
 
45. Posturing   
1 2 3 4 5 6 7 8 9 
  
46. Photosensitivity (sensitivity to light)  
1 2 3 4 5 6 7 8 9 
 
47. Spontaneous bleeding  
1 2 3 4 5 6 7 8 9 
 
48. Involuntary movements (e.g. rigors/ convulsions/ seizures)  
1 2 3 4 5 6 7 8 9 
 
49. Constipation  
1 2 3 4 5 6 7 8 9 
 
50. Blisters (on skin or mucous membrane)  
1 2 3 4 5 6 7 8 9 
 
51. Hallucinations  
1 2 3 4 5 6 7 8 9 
 
52. Wheezing/ difficulty breathing  
1 2 3 4 5 6 7 8 9 
 
53. Pallor  
1 2 3 4 5 6 7 8 9 
 
54. Change in walking (gait disturbance)  
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In studies involving young children  
 
55. Crying more than normal  
1 2 3 4 5 6 7 8 9 
  
56. Abnormal sucking (if breastfed)  
1 2 3 4 5 6 7 8 9 
  
57. Eating/drinking/ feeding less than normal  
1 2 3 4 5 6 7 8 9 
 
58. Irritable  
1 2 3 4 5 6 7 8 9 
 
59. Difficult to arouse  
1 2 3 4 5 6 7 8 9 
 
 
In studies involving pregnant women  
 
60. Increased uterine contractions (more than normal)  
1 2 3 4 5 6 7 8 9 
 
61. Baby movements less than normal  
1 2 3 4 5 6 7 8 9 
 
62. Vaginal bleeding  
1 2 3 4 5 6 7 8 9 
 
63. What is the maximum number of symptoms the participants can be reliably asked 






Please rate the following types of PICTORIAL QUESTIONING TOOLS to reflect 
to what extent you agree or disagree that each item is relevant and important and 
feasible for detecting participant-reported AE data. 
 
Please use the rating scale below in your assessment. 
 
1 = strongly disagree, 5 = neutral, 9 = strongly agree.  
 
Using photographs, drawings or pictures of the following signs and symptoms:  
 
64. Headache  
1 2 3 4 5 6 7 8 9 
 
65. Fever   
1 2 3 4 5 6 7 8 9 
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66. Loss of appetite  
1 2 3 4 5 6 7 8 9 
 
67. Diarrhoea  
1 2 3 4 5 6 7 8 9 
 
68. Skin rash  
1 2 3 4 5 6 7 8 9 
 
69. Mucous membrane blisters  
1 2 3 4 5 6 7 8 9 
 
70. Jaundice  
1 2 3 4 5 6 7 8 9 
  
71. Joint pain  
1 2 3 4 5 6 7 8 9 
72. Pruritus  
1 2 3 4 5 6 7 8 9 
 
 
Using photographs, drawings or pictures of the following body parts:  
 
73. Respiratory system  
1 2 3 4 5 6 7 8 9 
 
74. Gastrointestinal tract  
1 2 3 4 5 6 7 8 9 
 
75. Central nervous system  
1 2 3 4 5 6 7 8 9 
 
76. Skin  
1 2 3 4 5 6 7 8 9 
 
77. Whole body outline (to mark or point to)  





In round one you and other participants were asked if there were any other questioning 
methods or approaches considered relevant, important and feasible for asking 
participants about AEs apart from the general, structured or pictorial methods. The 
responses suggested as potentially useful depending on the context are listed below. 
   
Please rate each response to reflect to what extent you agree or disagree that each item 
is relevant and important and feasible for detecting participant-reported AEs in 
uncomplicated malaria treatment studies.  
 
Please use the rating scale below. 




1 = strongly disagree, 5 = neutral, 9 = strongly agree  
 
78. Collecting AE reports using mobile phones  
1 2 3 4 5 6 7 8 9 
 
79. Collecting AE reports using patient diaries  
1 2 3 4 5 6 7 8 9 
 
80. Collecting AE reports using group discussions.  
1 2 3 4 5 6 7 8 9 
 
81. Using flip charts, with a picture on one side for the participant and a written 
question for the investigator on the reverse side (to reduce investigator variability).  
1 2 3 4 5 6 7 8 9 
 
82. Using video footage on smartphones or tablets to show how some AEs which are 
difficult to depict on still images may manifest e.g. seizure activity.  
1 2 3 4 5 6 7 8 9 
 
 
83. Keeping an archive of digital photographs of AEs  
1 2 3 4 5 6 7 8 9 
 
84. Using an archive of visual analogue scales from day 0 throughout all the follow-
ups to measure potential AEs and any change in the occurrence of these events.  
1 2 3 4 5 6 7 8 9 
 
85. Openly engaging participants to discuss any concerns they have  
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Section B:   Asking participants about previous or NON-STUDY 
(CONCOMITANT) MEDICATION in uncomplicated malaria treatment studies.  
 
Please rate the following types of GENERAL QUESTIONS to reflect the extent to 
which you agree or disagree that each item is relevant and important and feasible to 
collect non-study medication data.  
 
Please note that the questions below are only examples of possible phrases, exact 
terminology may be context-specific.  
  
Please use the rating scale below in your assessment. 
 
1 = strongly disagree, 5 = neutral, 9 = strongly agree. 
 
86. General questions about the use of non-study medications (e.g. 'Have you taken 
any medications since your last visit/ in the past x days [trial-specific time scale]?').  
1 2 3 4 5 6 7 8 9 
  
  
Please rate the following types of STRUCTURED QUESTIONS to reflect the extent 
to which you agree or disagree that each item is relevant and important and feasible to 
collect non-study medication data. 
 
Please note that the questions are only examples of possible phrases, exact terminology 
may be context-specific.  
 
Please use the rating scale below in your assessment. 
 
1 = strongly disagree, 5 = neutral, 9 = strongly agree. 
 
Structured questions about source of medicine (e.g. 'Have you received any medication 
from a traditional healer since you were last seen here?' etc.) 
   
87. Medicine obtained from another health facility  
1 2 3 4 5 6 7 8 9 
 
88. Medicine obtained from a drug shop, pharmacy, chemical seller, the market (or 
equivalent)  
1 2 3 4 5 6 7 8 9 
 
89. Medicine obtained from a traditional healer, informal doctor (or equivalent)  
1 2 3 4 5 6 7 8 9 
 
90. Medicines already available in the home (from previous treatment courses).  
1 2 3 4 5 6 7 8 9 
  
91. Medicine obtained from family and/or friends  




92. Collecting and using naturally occurring herbs/remedies   
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1 2 3 4 5 6 7 8 9 
 
Structured questions about treatment class or specified indication (e.g. 'Have you 
taken an antibiotic, anything for malaria, vitamins?')  
 
93. Analgesics/ anti-inflammatory drugs  
1 2 3 4 5 6 7 8 9 
 
94. Antibiotics  
1 2 3 4 5 6 7 8 9 
 
95. Antihistamines  
1 2 3 4 5 6 7 8 9 
 
96. Antimalarial  
1 2 3 4 5 6 7 8 9 
 
97. Vitamins  
1 2 3 4 5 6 7 8 9 
 
98. Please rate the following statement to reflect the extent to which you feel it is 
relevant and important and feasible for collecting non-study medication data. 
 
“Participants should be asked about individual treatments by name according to 
what is known to be locally relevant?”  
1 2 3 4 5 6 7 8 9 
  
 
Please rate the following types of PICTORIAL AND/OR OTHER PHYSICAL 
TOOLS [used for questioning participants about non-study (concomitant) medication] 
to reflect the extent to which you agree or disagree that each item is relevant and 
important and feasible to collect non-study medication data.  
 
Please use the rating scale below in your assessment. 
 
1 = strongly disagree, 5 = neutral, 9 = strongly agree. 
 
The following pictorial questioning tools or physical samples:  
 
99. Showing photographs or drawings of commonly used drugs or drug packets   
1 2 3 4 5 6 7 8 9 
 
100. Showing samples of commonly used drugs or drug packets  
1 2 3 4 5 6 7 8 9 
 
101. Showing photographs or drawings of commonly used herbs/traditional remedies  
1 2 3 4 5 6 7 8 9 
 
102. Showing samples of commonly used herbs/ traditional remedies  
1 2 3 4 5 6 7 8 9 
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103. Asking participants to bring any non-study medication they may have taken 
before and/or during the trial/study to scheduled visits for a physical inspection  
1 2 3 4 5 6 7 8 9 
  
 Thank You!  
Thank you for taking the time to participate in this Delphi process. We appreciate your 
insights into this important and complex topic. For more information on this project, 
or if you are interested in collaborating with our research team, please contact Liz 
Allen at the University of Cape Town, South Africa (elizabeth.allen@uct.ac.za) or 
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Round Three Questionnaire 
 
Working towards consensus among malaria clinical researchers on methods used 
to elicit harms data in uncomplicated malaria clinical drug studies: A Delphi 
Process. 
 
Thank you for completing round two of the Delphi process. We would now like to 
invite you to complete the third round.  
 
In round two you and others taking part were presented with the collated suggestions 
from round one so that you could rate each type of question in terms of its relevance, 
importance and feasibility. We now present you with the summary of all responses 
from round two, along with your individual response, and we ask that you re-evaluate 
your rating score taking into consideration the summary of responses from the other 
experts taking part. Please refer back to your individual responses from round two 
when completing this round. Your individual responses will be sent to you via email 
within twenty-four hours of receiving the invitation to complete the third round. If you 
have not received your individual responses yet please contact Faikah Salie 
(faikah.salie@uct.ac.za) and she will resend it to you. 
 
For each item, we will ask you if you would like to change your rating score or 
maintain your original value. The aim of this Delphi process is to achieve consensus 
on a 'menu' of harmonized or standard types of core questions to be used in a variety 
of uncomplicated antimalarial treatment studies. The different types of questioning 
methods need not be mutually exclusive so you can recommend more than one type. 
 
Please keep in mind the focus of this Delphi process is safety (not efficacy), and in 
particular participants' subjective responses to questions about adverse events and 
concomitant (non-study drug) medicines. 
 
We would like to encourage you once again to complete this round of the Delphi to 




* The ACT Consortium is a group of researchers conducting projects relating to the implementation of 
Artemisinin-based combination therapies (ACT) for malaria treatment within Africa and Asia 
(www.actconsortium.org). This project is funded through a grant from the Bill & Melinda Gates 
Foundation to the London School of Hygiene & Tropical Medicine. 
 
 
Ethical approval for this study was granted by the University of Cape Town Research Ethics Committee. 
If you have any concerns regarding your rights and welfare as they relate to this study you can contact 
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We achieved consensus on some of the items in round two and we present them 
below. You are not asked to rate these items. 
   
Consensus was reached on all of the items listed below. This means that the panel 
collectively rated these items as being relevant, important and feasible for questioning 
participants in uncomplicated malaria treatment studies about AEs and concomitant 
medication using the different types of questioning methods mentioned in the Delphi. 
We defined consensus as having no less than 70 % of panellist selecting options which 
are within the same three-point region (1 - 3, 4 - 6, 7 - 9) containing the median. 
 
 
Asking participants about adverse events (AEs) in uncomplicated malaria 
treatment studies using GENERAL QUESTIONS:  
 
- Using an explicit question about change in health (e.g. 'Have you observed any 
change or new complaint since your last visit/ in the past x days [trial-specific 
time scale]?') 
 
Asking participants about adverse events (signs and symptoms) using 
STRUCTURED QUESTIONS: 
 








- Skin rash 
- Itching (no rash) 
- Peeling skin 
- Tinnitus (ringing in the ears)/ hearing problem 
- Sleep disturbance/ nightmares 
- Involuntary movements (e.g. rigors/ convulsions/ seizures) 
- Wheezing/ difficulty breathing 
 
In infants: 
- Eating/drinking/ feeding less than normal 
- Difficult to arouse 
 
In pregnant women 
- For Increased uterine contractions (more than normal) 
 
Additional questioning methods or approaches for asking participants about AEs 
apart from the general, structured or pictorial methods: 
 
- Keeping an archive of digital photographs of AEs. 
 
Asking participants about previous or non-study (concomitant) medication in 
uncomplicated malaria treatment studies using GENERAL QUESTIONS:  
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- General questions about the use of non-study medications (e.g. 'Have you taken 
any medications since your last visit/ in the past x days [trial-specific time 
scale]?'). 
 
Asking participants about source of medicines in uncomplicated malaria 
treatment studies using STRUCTURED QUESTIONS. 
We achieved consensus on the following sources of medicines: 
 
- Medicine obtained from another health facility 
- Medicine obtained from a drug shop, pharmacy, chemical seller, the market (or 
equivalent) 
- Medicine obtained from a traditional healer, informal doctor (or equivalent) 
- Medicines already available in the home (from previous treatment courses). 
- Collecting and using naturally occurring herbs/remedies 
 
 
Asking participants about ADVERSE EVENTS in uncomplicated malaria 
treatment studies 
 
Please state for each of the following types of GENERAL QUESTIONS previously 
asked of you, whether you would like to change your rating score. The summary of 
responses will be presented below each question. 
 
If you choose to change your rating, please use the rating scale below in your 
assessment. 
 
1 = strongly disagree, 5 = neutral, 9 = strongly agree.  
 
2. General question about feeling (e.g. 'How have you [has your child] been feeling 
since your last visit/ in the past x days [trial-specific time scale]?’)  
Summary of responses: 
Rating score Percentage of respondents 
1   6.3% 
2   18.8% 
3   6.3% 
4   6.3% 
5   12.5% 
6   0.0% 
7   12.5% 
8   6.3% 
9   31.3% 
Would you like to change your rating score?  
 Yes  
 No  
If yes, please select your new rating score below:  
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3. Question implying causality (e.g. 'Did your child experience any side effect from the 
drug since your last visit/ in the past x days [trial-specific time scale]?') 
Summary responses:  
Rating score Percentage of respondents 
1   12.5% 
2   6.3% 
3   25.0% 
4   6.3% 
5   12.5% 
6   6.3% 
7   18.8% 
8   0.0% 
9   12.5% 
Would you like to change your rating score?  
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
4. General question about past adverse reactions to treatments (e.g. 'Have you ever 
reacted badly to a drug or vaccine').  
Summary responses:  
Rating score Percentage of respondents 
1   18.8% 
2   0.0% 
3   6.3% 
4   18.8% 
5   6.3% 
6   0.0% 
7   6.3% 
8   12.5% 
9   31.3% 
Would you like to change your rating score?  
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
5. General question about rating any change in health (e.g. 'How do you rate your state 
of health after taking the study medicine?').  
Summary responses:  
Rating score Percentage of respondents 
1   18.8% 
2   0.0% 
3   6.3% 
4   12.5% 
5   6.3% 
6   12.5% 
7   25.0% 
8   18.8% 
9   0.0% 
Would you like to change your rating score? *This question is required.  
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 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
  
 
Asking participants about ADVERSE EVENTS in uncomplicated malaria 
treatment studies 
 
Please state for each of the following types of STRUCTURED QUESTIONS 
previously asked of you, whether you would like to change your rating score. The 
summary or responses will be presented below each question. 
 
If you choose to change your rating, please use the rating scale below in your 
assessment. 
 
1 = strongly disagree, 5 = neutral, 9 = strongly agree. 
 
Please note that the questions below are only examples of possible phrases, exact 
terminology may be context-specific.  
 
Questions about body parts, systems or functions (e.g. 'Have you experienced a 




Rating score Percentage of respondents 
1   12.5% 
2   6.3% 
3                      0.0% 
4   0.0% 
5   18.8% 
6   18.8% 
7   18.8% 
8   6.3% 
9   18.8% 
Would you like to change your rating score?  
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
  





Rating score Percentage of respondents 
1   6.3% 
2   12.5% 
3   0.0% 
4   0.0% 
5   18.8% 
6   6.3% 
7   25.0% 
8   12.5% 
9   18.8% 
Would you like to change your rating score?  
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
  
 8. Throat 
Summary responses: 
Rating score Percentage of respondents 
1   6.3% 
2   12.5% 
3   0.0 % 
4   6.3% 
5   12.5% 
6   12.5% 
7   18.8% 
8   12.5% 
9   18.8% 
 Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  




Rating score Percentage of respondents 
1   6.3% 
2   12.5% 
3   0.0% 
4   0.0% 
5   18.8% 
6   6.3% 
7   25.0% 
8   6.3% 
9   25.0% 
 Would you like to change your rating score? 
 Yes  
 No  
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If yes, please select your new rating score below:  














 Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  




Rating score Percentage of respondents 
1   6.3% 
2   6.3% 
3   0.0% 
4   0.0% 
5   18.8% 
6   12.5% 
7   37.5% 
8   6.3% 
9   12.5% 
 Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
12. Endocrine system (e.g. diabetes, thyroid) 
Summary responses:   
Rating score Percentage of respondents 
1   12.5% 
2   12.5% 
3   12.5% 
4   0.0% 
5   50.0% 
6   0.0% 
7   6.3% 
8   0.0% 
9   6.3% 
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 Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
13. Heart 
Summary responses:   
Rating score Percentage of respondents 
1   6.3% 
2   6.3% 
3   6.3% 
4   12.5% 
5   18.8% 
6   12.5% 
7   25.0% 
8   0.0% 
9   12.5% 
 Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
14. Lungs/Breathing 
Summary responses:   
Rating score Percentage of respondents 
1   6.3% 
2   0.0% 
3   0.0% 
4   0.0% 
5   25.0% 
6   12.5% 
7   31.3% 
8   12.5% 
9   12.5% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
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15. Lymphatic system 
Summary responses:   
Rating score Percentage of respondents 
1   18.8% 
2   12.5% 
3   12.5% 
4   0.0% 
5   37.5% 
6   0.0% 
7   12.5% 
8   0.0% 
9   6.3% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
16. Nervous system (e.g. seizures, migraines) 
Summary responses: 
 Rating score Percentage of respondents 
1   6.3% 
2   0.0% 
3   6.3% 
4   6.3% 
5   12.5% 
6   18.8% 
7   18.8% 
8   6.3% 
9   25.0% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  




Asking participants about SIGNS OR SYMPTOMS (including possible expected 
adverse drug reactions) in uncomplicated malaria treatment studies 
 
Please state for each of the following types of STRUCTURED QUESTIONS about 
signs or symptoms (including adverse drug reactions) previously asked of you, 
whether you would like to change your rating score. The summary or responses will 
be presented below each question. 
 
If you choose to change your rating, please use the rating scale below in your 
assessment. 
 
1 = strongly disagree, 5 = neutral, 9 = strongly agree. 
   
17. Tiredness/ fatigue/ weakness/ lethargy 
Round Three Questionnaire___________________________________________Appendices 
31 
 
Summary responses:   
Rating score Percentage of respondents 
1   12.5% 
2   0.0% 
3   0.0% 
4   0.0% 
5   6.3% 
6   25.0% 
7   0.0% 
8   31.3% 
9   25.0% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
 
18. Muscle pain 
Summary responses: 
Rating score Percentage of respondents 
1   12.5% 
2   0.0% 
3   0.0% 
4   12.5% 
5   12.5% 
6   0.0% 
7   0.0% 
8   31.3% 
9   31.3% 
 Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
19. Joint pain 
Summary responses: 
Rating score Percentage of respondents 
1   12.5% 
2   0.0% 
3   6.3% 
4   0.0% 
5   6.3% 
6   12.5% 
7   0.0% 
8   31.3% 
9   31.3% 
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Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
20. Abdominal pain 
Summary responses:   
Rating score Percentage of respondents 
1   12.5% 
2   0.0% 
3   0.0% 
4   0.0% 
5   6.3% 
6   18.8% 
7   6.3% 
8   18.8% 
9   37.5% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
21. Mood/ behavioural change 
Summary responses:   
Rating score Percentage of respondents 
1   14.3% 
2   0.0% 
3   0.0% 
4   0.0% 
5   14.3% 
6   14.3% 
7   21.4% 
8   21.4% 
9   14.3% 
 Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
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22. Non-allergic skin rash (e.g. scabies) 
Summary responses: 
Rating score Percentage of respondents 
1   25.0% 
2   0.0% 
3   12.5% 
4   6.3% 
5   12.5% 
6   18.8% 
7   12.5% 
8   6.3% 
9   6.3% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
23. Allergic skin rash (e.g. some forms of urticaria) 
Summary responses: 
Rating score Percentage of respondents 
1   25.0% 
2   0.0% 
3   0.0% 
4   0.0% 
5   6.3% 
6   6.3% 
7   18.8% 
8   31.3% 
9   12.5% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
24. Skin abnormalities 
Summary responses: 
Rating score Percentage of respondents 
1   12.5% 
2   0.0% 
3   0.0% 
4   6.3% 
5   12.5% 
6   12.5% 
7   18.8% 
8   18.8% 
9   18.8% 
 Would you like to change your rating score? 
 Yes  
 No  
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If yes, please select your new rating score below:  




Rating score Percentage of respondents 
1   12.5% 
2   0.0% 
3   6.3% 
4   0.0% 
5   6.3% 
6   6.3% 
7   12.5% 
8   25.0% 
9   31.3% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
26. Vision/sight problem 
Summary responses: 
Rating score Percentage of respondents 
1   12.5% 
2   0.0% 
3   12.5% 
4   0.0% 
5   6.3% 
6   6.3% 
7   0.0% 
8   25.0% 
9   37.5% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
27. Change in urine colour 
Summary responses: 
Rating score Percentage of respondents 
1   12.5% 
2   0.0% 
3   0.0% 
4   0.0% 
5   25.0% 
6   6.3% 
7   12.5% 
8   18.8% 
9   25.0% 
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 Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  




Rating score Percentage of respondents 
1   12.5% 
2   0.0% 
3   0.0% 
4   6.3% 
5   12.5% 
6   6.3% 
7   18.8% 
8   25.0% 
9   18.8% 
 Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  














Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
  





Rating score Percentage of respondents 
1   12.5% 
2   0.0% 
3   0.0% 
4   6.3% 
5   12.5% 
6   6.3% 
7   25.0% 
8   25.0% 
9   12.5% 
 Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
31. Oculogyric crisis 
Summary responses: 
Rating score Percentage of respondents 
1   12.5% 
2   6.3% 
3   12.5% 
4   6.3% 
5   18.8% 
6   12.5% 
7   18.8% 
8   6.3% 
9   6.3% 
 Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
32. Posturing  
Summary responses:   










 Would you like to change your rating score? 
 Yes  
 No  
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If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
33. Photosensitivity (sensitivity to light) 
Summary responses: 
Rating score Percentage of respondents 
1   12.5% 
2   0.0% 
3   0.0% 
4   6.3% 
5   18.8% 
6   0.0% 
7   31.3% 
8   12.5% 
9   18.8% 
 Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
34. Spontaneous bleeding 
Summary responses:   
Rating score Percentage of respondents 
1   6.3% 
2   0.0% 
3   0.0% 
4   0.0% 
5   12.5% 
6   18.8% 
7   18.8% 
8   12.5% 
9   31.3% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
35. Constipation 
Summary responses:   
Rating score Percentage of respondents 
1   6.3% 
2   0.0% 
3   12.5% 
4   0.0% 
5   18.8% 
6   6.3% 
7   12.5% 
8   18.8% 
9   25.0% 
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Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
36. Blisters (on skin or mucous membrane) 
Summary responses:   
Rating score Percentage of respondents 
1   12.5% 
2   0.0% 
3   0.0% 
4   6.3% 
5   6.3% 
6   6.3% 
7   18.8% 
8   25.0% 
9   25.0% 
 Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
37. Hallucinations 
Summary responses:   
Rating score Percentage of respondents 
1   12.5% 
2   0.0% 
3   0.0% 
4   0.0% 
5   18.8% 
6   12.5% 
7   12.5% 
8   25.0% 
9   18.8% 
 Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
  




Summary responses:   
Rating score Percentage of respondents 
1   6.3% 
2   6.3% 
3   6.3% 
4   0.0% 
5   18.8% 
6   18.8% 
7   6.3% 
8   18.8% 
9   18.8% 
 Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
39. Change in walking (gait disturbance) 
Summary responses:   
Rating score Percentage of respondents 
1   13.3 % 
2   0.0% 
3   6.7% 
4   0.0% 
5   20.0% 
6   13.3% 
7   6.7% 
8   20.0% 
9   20.0% 
 Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
 
In studies involving young children  
40. Crying more than normal 
Summary responses: 
Rating score Percentage of respondents 
1   12.5% 
2   0.0% 
3   0.0% 
4   0.0% 
5   18.8% 
6   6.3% 
7   12.5% 
8   25.0% 
9   25.0% 
Would you like to change your rating score? 
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 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
41. Abnormal sucking (if breastfed) 
Summary responses: 
Rating score Percentage of respondents 
1   12.5% 
2   0.0% 
3   0.0% 
4   0.0% 
5   18.8% 
6   6.3% 
7   12.5% 
8   12.5% 
9   37.5% 
 Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  




Rating score Percentage of respondents 
1   12.5% 
2   6.3% 
3   0.0% 
4   0.0% 
5   6.3% 
6   6.3% 
7   12.5% 
8   31.3% 
9   25.0% 
 Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
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In studies involving pregnant women  
43. Baby movements less than normal 
Summary responses: 
Rating score Percentage of respondents 
1   12.5% 
2   0.0% 
3   0.0% 
4   0.0% 
5   12.5% 
6   6.3% 
7   12.5% 
8   18.8% 
9   37.5% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
44. Vaginal bleeding 
Summary responses:   
Rating score Percentage of respondents 
1   6.3% 
2   0.0% 
3   0.0% 
4   0.0% 
5   12.5% 
6   12.5% 
7   12.5% 
8   12.5% 
9   43.8% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
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Asking participants about ADVERSE EVENTS in uncomplicated malaria 
treatment studies 
 
Please state for each of the following types of PICTORIAL QUESTIONING 
TOOLS you were previously asked about, whether you would like to change your 
rating score. The summary or responses will be presented below each question. 
 
If you choose to change your rating, please use the rating scale below in your 
assessment. 
 
1 = strongly disagree, 5 = neutral, 9 = strongly agree. 
   




Rating score Percentage of respondents 
1   33.3% 
2   6.7% 
3   0.0% 
4   13.3% 
5   26.7% 
6   0.0% 
7   0.0% 
8   20.0% 
9   0.0% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  




46. Fever  
Summary responses:   
Rating score Percentage of respondents 
1   26.7% 
2   13.3% 
3   0.0% 
4   13.3% 
5   20.0% 
6   0.0% 
7   13.3% 
8   13.3% 
9   0.0% 
 Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
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47. Loss of appetite 
Summary responses:   
Rating score Percentage of respondents 
1   33.3% 
2   6.7% 
3   0.0% 
4   13.3% 
5   26.7% 
6   0.0% 
7   13.3% 
8   6.7% 
9   0.0% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
  
48. Diarrhoea 
Summary responses:   
Rating score Percentage of respondents 
1   2.0% 
2   6.7% 
3   0.0% 
4   13.3% 
5   20.0% 
6   6.7% 
7   6.7% 
8   20.0% 
9   6.7% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
49. Skin rash 
Summary responses:   
Rating score Percentage of respondents 
1   13.3% 
2   6.7% 
3   0.0% 
4   0.0% 
5   20.0% 
6   6.7% 
7   0.0% 
8   26.7% 
9   26.7% 
Would you like to change your rating score? 
 Yes  
 No  
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If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
50. Mucous membrane blisters 
Summary responses:   
Rating score Percentage of respondents 
1   7.1% 
2   7.1% 
3   0.0% 
4   0.0% 
5   14.3% 
6   7.1% 
7   14.3% 
8   21.4% 
9   28.6% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
51. Jaundice 
Summary responses:   
Rating score Percentage of respondents 
1   0.0% 
2   6.7% 
3   6.7% 
4   0.0% 
5   26.7% 
6   13.3% 
7   13.3% 
8   13.3% 
9   20.0% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
52. Joint pain 
Summary responses: 
Rating score Percentage of respondents 
1   26.7% 
2   13.3% 
3   6.7% 
4   0.0% 
5   33.3% 
6   0.0% 
7   13.3% 
8   6.7% 
9   0.0% 
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Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
53. Pruritus 
Summary responses:   
Rating score Percentage of respondents 
1   20.0% 
2   6.7% 
3   13.3% 
4   0.0% 
5   33.3% 
6   6.7 % 
7   13.3% 
8   6.7% 
9   0.0% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
 
Using photographs, drawings or pictures of the following body parts  
54. Respiratory system 
Summary responses:   
Rating score Percentage of respondents 
1   13.3% 
2   6.7% 
3   20.0% 
4   6.7% 
5   26.7% 
6   6.7% 
7   13.3% 
8   0.0% 
9   6.7% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
 
55. Gastrointestinal tract 
Summary responses:   
Rating score Percentage of respondents 
1   13.3% 
2   6.7 % 
3   20.0% 
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4   6.7% 
5   26.7% 
6   6.7% 
7   6.7% 
8   6.7% 
9   6.7% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
56. Central nervous system 
Summary responses:   
Rating score Percentage of respondents 
1   13.3% 
2   20.0% 
3   6.7% 
4   13.3% 
5   26.7% 
6   0.0% 
7   0.0% 
8   6.7% 
9   13.3% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
57. Skin 
Summary responses:   
Rating score Percentage of respondents 
1   13.3% 
2   6.7% 
3   13.3% 
4   0.0% 
5   20.0% 
6   0.0% 
7   20.0% 
8   0.0% 
9   26.7% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
  




58. Whole body outline (to mark or point to) 
Summary responses:   
Rating score Percentage of respondents 
1   14.3% 
2   0.0% 
3   7.1% 
4   7.1% 
5   7.1% 
6   7.1% 
7   7.1% 
8   21.4% 
9   28.6% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  





In round two you and other participants were asked to rate the additional methods or 
approaches suggested by some respondents as potentially useful (depending on the 
context), in terms of their relevance; importance and feasibility  for asking participants 
about AEs apart from general; structured or pictorial methods or approaches. 
 
Please state for each item below whether you would like to change your rating score. 
The summary or responses will be presented below each question. 
 
If you choose to change your rating, please use the rating scale below in your 
assessment. 
 
1 = strongly disagree, 5 = neutral, 9 = strongly agree.  
 
59. Collecting AE reports using mobile phones 
Summary responses:   
Rating score Percentage of respondents 
1   0.0% 
2   0.0% 
3   0.0% 
4   6.7% 
5   33.3% 
6   6.7% 
7   6.7% 
8   26.7% 
9   20.0% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
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60. Collecting AE reports using patient diaries 
Summary responses:   
Rating score Percentage of respondents 
1   0.0% 
2   0.0% 
3   6.7% 
4   13.3% 
5   13.3% 
6   6.7% 
7   6.7% 
8   20.0% 
9   33.3% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
61. Collecting AE reports using group discussions 
Summary responses:   
Rating score Percentage of respondents 
1   13.3% 
2   0.0% 
3   13.3% 
4   6.7% 
5   26.7% 
6   13.3% 
7   6.7% 
8   13.3% 
9   6.7% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
62. Using flip charts, with a picture on one side for the participant and a written 
question for the investigator on the reverse side (to reduce investigator variability). 
Summary responses: 
Rating score Percentage of respondents 
1   6.7% 
2   0.0% 
3   6.7% 
4   0.0% 
5   46.7% 
6   6.7% 
7   13.3% 
8   6.7% 
9   13.3% 
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Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
63. Using video footage on smartphones or tablets to show how some AEs which are 
difficult to depict on still images may manifest e.g. seizure activity. 
Summary responses:   
Rating score Percentage of respondents 
1   0.0% 
2   0.0% 
3   0.0% 
4   6.7% 
5   33.3% 
6   6.7% 
7   13.3% 
8   13.3% 
9   26.7% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
64. Using an archive of visual analogue scales from day 0 throughout all the follow-
ups to measure potential AEs and any change in the occurrence of these events. 
Summary responses:   
Rating score Percentage of respondents 
1   6.7% 
2   0.0% 
3   0.0% 
4   0.0% 
5   26.7% 
6   20.0% 
7   26.7% 
8   13.3% 
9   6.7% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
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65. Openly engaging participants to discuss any concerns they have. 
Summary responses:   
Rating score Percentage of respondents 
1   7.1% 
2   0.0% 
3   0.0% 
4   7.1% 
5   21.4% 
6   0.0% 
7   21.4% 
8   14.3% 
9   28.6% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  




Asking participants about NON-STUDY MEDICATION in uncomplicated 
malaria treatment studies 
 
Please state for each of the following types of STRUCTURED QUESTIONS  used 
to collect non-study medication data previously asked of you, whether you would like 
to change your rating score. The summary or responses will be presented below each 
question. 
 
If you choose to change your rating, please use the rating scale below in your 
assessment. 
 
1 = strongly disagree, 5 = neutral, 9 = strongly agree. 
 
Please note that the questions are only examples of possible phrases, exact terminology 
may be context-specific.  
 
Structured questions about source of medicine (e.g. 'Have you received any 
medication from a traditional healer since you were last seen here?' etc.)  
 
66. Medicine obtained from family and/or friends 
Summary responses:   
Rating score Percentage of respondents 
1   6.7% 
2   0.0% 
3   0.0% 
4   0.0% 
5   26.7% 
6   0.0% 
7   13.3% 
8   20.0% 
9   33.3% 
Would you like to change your rating score? 
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 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
Structured questions about treatment class or specified indication (e.g. 'Have you 
taken an antibiotic, anything for malaria, vitamins?')  
 
67. Analgesics/ anti-inflammatory drugs 
Summary responses:   
Rating score Percentage of respondents 
1   6.7% 
2   13.3% 
3   0.0% 
4   0.0% 
5   13.3% 
6   13.3% 
7   20.0% 
8   13.3% 
9   20.0% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
68. Antibiotics 
Summary responses:   
Rating score Percentage of respondents 
1   6.7% 
2   6.7% 
3   0.0% 
4   0.0% 
5   13.3% 
6   6.7% 
7   40.0% 
8   13.3% 
9   13.3% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
  




Summary responses:   
Rating score Percentage of respondents 
1   6.7% 
2   13.3% 
3   0.0% 
4   0.0% 
5   26.7% 
6   13.3% 
7   26.7% 
8   13.3% 
9   0.0% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  




Rating score Percentage of respondents 
1   6.7% 
2   6.7% 
3   0.0% 
4   0.0% 
5   20.0% 
6   6.7% 
7   6.7% 
8   20.0% 
9   33.3% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  




Rating score Percentage of respondents 
1   6.7% 
2   6.7% 
3   6.7% 
4   0.0% 
5   33.3% 
6   6.7% 
7   13.3% 
8   20.0% 
9   6.7% 
Would you like to change your rating score? 
 Yes  
 No  
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If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
   
 72. Please rate the following statement to reflect the extent to which you feel it is 
relevant and important and feasible for collecting non-study medication data. 
  
“Participants should be asked about individual treatments by name according to what 
is known to be locally relevant.”  
 Summary responses: 
Rating score Percentage of respondents 
1   6.7% 
2   0.0% 
3   0.0% 
4   0.0% 
5   13.3% 
6   13.3% 
7   20.0% 
8   20.0% 
9   26.7% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
  
    
Asking participants about in uncomplicated malaria treatment studies 
 
Please state for each of the following types of PICTORIAL AND/OR OTHER 
PHYSICAL TOOLS used for questioning participants about non-study 
(concomitant) medication previously asked of you, whether you would like to change 
your rating score. The summary or responses will be presented below each question. 
 
If you choose to change your rating, please use the rating scale below in your 
assessment. 
 
1 = strongly disagree, 5 = neutral, 9 = strongly agree.  
 
The following pictorial questioning tools or physical samples:  
 
73. Showing photographs or drawings of commonly used drugs or drug packets  
Summary responses: 
Rating score Percentage of respondents 
1   6.7% 
2   0.0% 
3   0.0% 
4   0.0% 
5   13.3% 
6   13.3% 
7   20.0% 
8   13.3% 
9   33.3% 
Round Three Questionnaire___________________________________________Appendices 
54 
 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
  
  74. Showing samples of commonly used drugs or drug packets 
Summary responses: 
Rating score Percentage of respondents 
1   6.7% 
2   0.0% 
3   0.0% 
4   0.0% 
5   13.3% 
6   13.3% 
7   13.3% 
8   33.3% 
9   20.0% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
  
75. Showing photographs or drawings of commonly used herbs/traditional remedies 
Summary responses: 
Rating score Percentage of respondents 
1   6.7% 
2   0.0% 
3   0.0% 
4   0.0% 
5   13.3% 
6   26.7% 
7   20.0% 
8   13.3% 
9   20.0% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
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76. Showing samples of commonly used herbs/ traditional remedies 
Summary responses: 
Rating score Percentage of respondents 
1   7.1% 
2   0.0% 
3   0.0% 
4   0.0% 
5   21.4% 
6   14.3% 
7   21.4% 
8   21.4% 
9   14.3% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  
1 2 3 4 5 6 7 8 9 
 
77. Asking participants to bring any non-study medication they may have taken before 
and/or during the trial/study to scheduled visits for a physical inspection 
Summary responses: 
Rating score Percentage of respondents 
1   14.3% 
2   7.1% 
3   0.0% 
4   0.0% 
5   14.3% 
6   7.1% 
7   21.4% 
8   7.1% 
9   28.6% 
Would you like to change your rating score? 
 Yes  
 No  
If yes, please select your new rating score below:  




Thank You!  
  
Thank you for taking the time to participate in this Delphi process. We appreciate your 
insights into this important and complex topic. 
  
For more information on this project, or if you are interested in collaborating with our 
research team, please contact Liz Allen at the University of Cape Town, South Africa 
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Working towards consensus on methods used to collect participant-reported 
harms-related data in uncomplicated malaria clinical drug trials/studies 
  
What will being part of this Delphi require from you? 
The aim of Delphi is to achieve consensus about a topic. In the first round we will 
present an overview of the methods used generally in clinical research, and more 
specifically in malaria clinical drug studies, to detect, assess and record participant-
reported data used for assessing harms (adverse events and previous/concomitant 
medications). Then we will ask participants to recommend any additional approaches 
to obtain these data (for those who took part in our survey, this may involve a repeat 
of some of those questions). In the second round you will be asked to rank the 
methods/approaches in terms of their relevance, importance and feasibility in 
uncomplicated malaria drug studies. In subsequent rounds we will send you a summary 
of the group’s rankings, and where your own rankings fall. You will then be able to 
maintain your rankings or amend them. By the final (3rd of 4th) round we hope to 
reach consensus between the panellists about which approaches, if any, are suitable 
for taking forward for testing and possible harmonisation within malaria clinical 
studies. 
 
As a participant you may benefit from discussion with other malaria researchers with 
considerable experience and expertise in this field of research. A disadvantage is that 
a Delphi can be time consuming and require commitment to complete all rounds. We 
have, however, kept our questions as brief as possible while still ensuring richness of 
the data collected. 
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Throughout the Delphi your identity will be concealed from other panellists and the 
study investigators (a research assistant not otherwise involved will manage 
communications). After the Delphi you are free to reveal your identity if desired. You 
have two weeks to submit responses to each round. We strongly encourage you to 
complete all stages to add to the richness of the data collected and rigour of the study. 
If for any reason you decide you no longer want to participate, however, you are free 
to withdraw at any point. 
 
If you have any queries please contact the study investigators Ms Nyaradzo 
Mandimika (dzadz81@gmail.com) or Elizabeth Allen (elizabeth.allen@uct.ac.za). If 
you have any concerns regarding your rights and welfare as they relate to this study 
you can contact the University of Cape Town Human Research Ethics Committee 
(shuretta.thomas@uct.ac.za or on +27214066338). 
 
If you would like to continue with the Delphi please click here [URL link]. Please note 




The ACT Consortium is a group of researchers conducting projects relating to the 
implementation of Artemisinin-based combination therapies (ACT) for malaria treatment 
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Working towards consensus on methods used to collect participant-reported 
harms-related data in uncomplicated malaria clinical drug trials/studies 
 
In order to discuss the merits and methods of harmonising the way we question 
antimalarial drug research participants to collect medical histories, adverse events and 
concomitant medication data, we have summarised some pertinent literature for 
prospective Delphi panellists, including our own work for this particular project.  
 
The results of clinical research studies, syntheses of reports, and analyses of pooled 
individual participant harms data, are influenced by the methods used to collect such 
data. Different questioning methods about their health may elicit non-comparable 
responses from participants (Ioannidis et al, 2006). However, there is no consensus 
regarding the detail of how participants (in general or for malaria) should be 
questioned in order to generate medical history, adverse event (AEs) or 
previous/concomitant medication data. For AEs there is evidence that more detailed 
questioning (e.g. with reference to a checklist of possible symptoms or body functions) 
enhances responses (Bent et al, 2006; Greenhill et al, 2004). However, the effect of 
different question methods on the nature of reports is less clear. There are concerns 
that detailed methods could produce a deluge of ‘noise’, unhelpful AEs that cannot be 
distinguished from background rates, and that spontaneously reported events are either 
more clinically meaningful or more likely to be related to a trial drug compared to 
placebo (Barber & Santanello 1995; Wernicke et al, 2005).  
 
There is a dearth of research about the way medical histories and previous/concomitant 
medications are elicited in clinical research, despite evidence that participants fail to 
report medication use when asked (Hodel et al, 2009). In other areas of 
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pharmacoepidemiology, including case-control or cohort studies and administrative 
databases, there has been methodological investigation regarding the accuracy of self-
reported past medical conditions and medications, through comparison with medical 
or prescription records (West et al, 2005). In those contexts, recall of medical history 
appears dependent somewhat on the type of condition, its significance, and a 
willingness to share information. Pattern-of-use is influential in recall of past 
medications, and indication- or medication-specific questions increase prevalence 
estimates compared to open-ended questions (Gama et al, 2009).  
 
In our own work we explored the process of participant-reported health and 
previous/concomitant data elicitation in malaria and HIV drug interaction trials in 
South Africa and Tanzania (Allen et al, 2013a). Reports obtained through different 
questioning types (a general enquiry, followed by checklists of possible health issues 
and medications, and finally an in-depth interview) were compared. We also 
qualitatively explored participants’ experiences of illness and use of medications, and 
their reporting behaviour. There was an overall increase in the number of reports from 
general enquiry, through checklists, to in-depth interview. Using checklists and 
interviews appeared to facilitate recognition of health issues and medications used, and 
consideration of what to report. Information was sometimes not reported initially 
because participants either ‘forgot’, the event or medication had ‘low significance to 
them’, it was ‘considered not relevant’, or because of ‘perceived negative 
consequences of reporting’. South African inpatient malaria negative/HIV positive 
volunteers exhibited a ‘trial citizenship’, working to achieve the researchers’ goals, 
compared to Tanzanian malaria outpatients who sometimes deferred responsibility for 
identifying which items to report to the trial doctor. The different trial contexts thus 
appeared to cultivate some specific conditions that had a role in mediating recognition, 
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reporting and articulation of these important variables.  
 
Participants in both sites overwhelmingly recommended that more detailed 
questioning (checklists or in-depth interviews) helped them to report. Investigators, 
meanwhile, spoke in their own focus group discussions of the challenge of eliciting 
comprehensive but relevant data when we will never know everything. For well-
studied drugs, the focus of more detailed questioning could be on known or an 
anticipated risk, combined with general enquires to detect anything else. But it is a 
quandary whether to probe for AEs that are perhaps insignificant or irrelevant to both 
investigators and participants. There was, however, concern that selective detailed 
questioning could miss minor illness that impacts on adherence, and thus efficacy and 
an increased risk of malaria resistance at a population level. These clinicians, reflecting 
how patients may be intimidated by them despite them being at pains to be otherwise, 
suggested that other cadres of staff be involved to overcome barriers to reporting, 
whether in designing elicitation strategies (social scientists), questioning participants 
(nurses or social scientists) or interpreting safety results (anthropologists) 
 
We propose, based on our own research, that some barriers to reporting may be 
overcome by using a checklist-type of method, while others may require a different 
approach (such as counselling participants to quell potential concerns about reporting). 
However, our work was limited to two clinical sites and therefore may not be 
generalizable. There may be a need for researchers to reflect on their own context when 
considering potential barriers to reporting and possible solutions in terms of 
questioning methods or approaches. To contribute to knowledge about this area we 
recently conducted a survey of antimalarial drug clinical researchers about the methods 
they used in their own studies (Allen et al, 2013b). In this, currently unpublished, 
Literature and Survey Results Summary_________________________________Appendices 
63 
 
survey we included 52 responses from 25 counties; 87% working at an investigational 
site and 75% reporting about an interventional study. For AEs, questioning in 31% of 
interventional studies was a combination of general (e.g. open questions about health) 
and structured (e.g. reference to specific health-related items), 26% used structured 
only and 18% general only. No observational studies used general questioning alone. 
A minority of studies incorporated pictorial tools. Rationales for the questioning 
approach included: standardisation of assessment or data capture, specificity or 
comprehensiveness of data sought, avoiding suggesting a response, feasibility, and 
seeking to understand participants’ perceptions. Most respondents considered the 
approach they reported as optimal, though several later reconsidered this. Combining 
general and structured questions about non-study drug use were considered useful for 
revealing and identifying specific medicines, while pictures were said to enhance 
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as the main manuscript file and your bib/bbl file as a dependent file. Please also convert 
your TeX file into a PDF and submit this PDF as an additional file with the name 
'Reference PDF'. This PDF will be used by internal staff as a reference point to check 
the layout of the article as the author intended. Please also note that all figures must be 
coded at the end of the TeX file and not inline. 
If you have used another template for your manuscript, or if you do not wish to use 
BibTeX, then please submit your manuscript as a DVI file. We do not recommend 
converting to RTF. 
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Overview of manuscript sections for Research Articles 
Manuscripts for Research Articles submitted to Malaria Journal should be divided 
into the following sections (in this order): 
 Title page 
 Abstract 
 Keywords 
 Background  
 Methods  
 Results and discussion 
 Conclusions 
 List of abbreviations used (if any) 
 Competing interests 
 Authors' contributions 




 Illustrations and figures (if any) 
 Tables and captions 
 Preparing additional files 
The Accession Numbers of any nucleic acid sequences, protein sequences or atomic 
coordinates cited in the manuscript should be provided, in square brackets and include 
the corresponding database name; for example, [EMBL:AB026295, 
EMBL:AC137000, DDBJ:AE000812, GenBank:U49845, PDB:1BFM, Swiss-
Prot:Q96KQ7, PIR:S66116]. 
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The databases for which we can provide direct links are: EMBL Nucleotide Sequence 
Database (EMBL), DNA Data Bank of Japan (DDBJ), GenBank at the NCBI 
(GenBank), Protein Data Bank (PDB), Protein Information Resource (PIR) and the 
Swiss-Prot Protein Database (Swiss-Prot). 
For reporting standards please see the information in the About section.  
Title page 
The title page should: 
 provide the title of the article 
 list the full names, institutional addresses and email addresses for all authors 
 indicate the corresponding author 
Please note: 
 the title should include the study design, for example "A versus B in the 
treatment of C: a randomized controlled trial X is a risk factor for Y: a case 
control study" 
 abbreviations within the title should be avoided 
 if a collaboration group should be listed as an author, please list the Group 
name as an author. If you would like the names of the individual members of 
the Group to be searchable through their individual PubMed records, please 
include this information in the “acknowledgements” section in accordance with 
the instructions below. Please note that the individual names may not be 
included in the PubMed record at the time a published article is initially 
included in PubMed as it takes PubMed additional time to code this 
information. 
Abstract 
The Abstract of the manuscript should not exceed 350 words and must be structured 
into separate sections: Background, the context and purpose of the study; Methods, 
how the study was performed and statistical tests used; Results, the main findings; 
Conclusions, brief summary and potential implications. Please minimize the use of 
abbreviations and do not cite references in the abstract. Trial registration, if your 
research reports the results of a controlled health care intervention, please list your trial 
registry, along with the unique identifying number (e.g. Trial registration: Current 
Controlled Trials ISRCTN73824458). Please note that there should be no space 
between the letters and numbers of your trial registration number. We recommend 
manuscripts that report randomized controlled trials follow the CONSORT extension 
for abstracts. 
Keywords 
Three to ten keywords representing the main content of the article. 
Background  
The Background section should be written in a way that is accessible to researchers 
without specialist knowledge in that area and must clearly state - and, if helpful, 
illustrate - the background to the research and its aims. Reports of clinical research 
should, where appropriate, include a summary of a search of the literature to indicate 
why this study was necessary and what it aimed to contribute to the field. The section 
should end with a brief statement of what is being reported in the article. 
Methods  
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The methods section should include the design of the study, the setting, the type of 
participants or materials involved, a clear description of all interventions and 
comparisons, and the type of analysis used, including a power calculation if 
appropriate. Generic drug names should generally be used. When proprietary brands 
are used in research, include the brand names in parentheses in the Methods section. 
For studies involving human participants a statement detailing ethical approval and 
consent should be included in the methods section. For further details of the journal's 
editorial policies and ethical guidelines see 'About this journal'. 
For further details of the journal's data-release policy, see the policy section in 'About 
this journal'. 
Results and discussion 
The Results and discussion may be combined into a single section or presented 
separately. Results of statistical analysis should include, where appropriate, relative 
and absolute risks or risk reductions, and confidence intervals. The Results and 
discussion sections may also be broken into subsections with short, informative 
headings.  
Conclusions 
This should state clearly the main conclusions of the research and give a clear 
explanation of their importance and relevance. Summary illustrations may be included. 
List of abbreviations 
If abbreviations are used in the text they should be defined in the text at first use, and 
a list of abbreviations can be provided, which should precede the competing interests 
and authors' contributions. 
Competing interests 
A competing interest exists when your interpretation of data or presentation of 
information may be influenced by your personal or financial relationship with other 
people or organizations. Authors must disclose any financial competing interests; they 
should also reveal any non-financial competing interests that may cause them 
embarrassment were they to become public after the publication of the manuscript. 
Authors are required to complete a declaration of competing interests. All competing 
interests that are declared will be listed at the end of published articles. Where an 
author gives no competing interests, the listing will read 'The author(s) declare that 
they have no competing interests'. 
When completing your declaration, please consider the following questions: 
Financial competing interests 
 In the past three years have you received reimbursements, fees, funding, or 
salary from an organization that may in any way gain or lose financially from 
the publication of this manuscript, either now or in the future? Is such an 
organization financing this manuscript (including the article-processing 
charge)? If so, please specify. 
 Do you hold any stocks or shares in an organization that may in any way gain 
or lose financially from the publication of this manuscript, either now or in the 
future? If so, please specify. 
 Do you hold or are you currently applying for any patents relating to the content 
of the manuscript? Have you received reimbursements, fees, funding, or salary 
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from an organization that holds or has applied for patents relating to the content 
of the manuscript? If so, please specify. 
 Do you have any other financial competing interests? If so, please specify. 
Non-financial competing interests  
Are there any non-financial competing interests (political, personal, religious, 
ideological, academic, intellectual, commercial or any other) to declare in relation to 
this manuscript? If so, please specify. 
If you are unsure as to whether you, or one your co-authors, has a competing interest 
please discuss it with the editorial office. 
Authors' contributions 
In order to give appropriate credit to each author of a paper, the individual 
contributions of authors to the manuscript should be specified in this section. 
According to ICMJE guidelines, An 'author' is generally considered to be someone 
who has made substantive intellectual contributions to a published study. To qualify 
as an author one should 1) have made substantial contributions to conception and 
design, or acquisition of data, or analysis and interpretation of data; 2) have been 
involved in drafting the manuscript or revising it critically for important intellectual 
content; 3) have given final approval of the version to be published; and 4) agree to be 
accountable for all aspects of the work in ensuring that questions related to the 
accuracy or integrity of any part of the work are appropriately investigated and 
resolved. Each author should have participated sufficiently in the work to take public 
responsibility for appropriate portions of the content. Acquisition of funding, 
collection of data, or general supervision of the research group, alone, does not justify 
authorship.  
We suggest the following kind of format (please use initials to refer to each author's 
contribution): AB carried out the molecular genetic studies, participated in the 
sequence alignment and drafted the manuscript. JY carried out the immunoassays. MT 
participated in the sequence alignment. ES participated in the design of the study and 
performed the statistical analysis. FG conceived of the study, and participated in its 
design and coordination and helped to draft the manuscript. All authors read and 
approved the final manuscript.  
All contributors who do not meet the criteria for authorship should be listed in an 
acknowledgements section. Examples of those who might be acknowledged include a 
person who provided purely technical help, writing assistance, a department chair who 
provided only general support, or those who contributed as part of a large collaboration 
group. 
Authors' information 
You may choose to use this section to include any relevant information about the 
author(s) that may aid the reader's interpretation of the article, and understand the 
standpoint of the author(s). This may include details about the authors' qualifications, 
current positions they hold at institutions or societies, or any other relevant background 
information. Please refer to authors using their initials. Note this section should not be 
used to describe any competing interests. 
Acknowledgements 
Please acknowledge anyone who contributed towards the article by making substantial 
contributions to conception, design, acquisition of data, or analysis and interpretation 
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of data, or who was involved in drafting the manuscript or revising it critically for 
important intellectual content, but who does not meet the criteria for authorship. Please 
also include the source(s) of funding for each author, and for the manuscript 
preparation. Authors must describe the role of the funding body, if any, in design, in 
the collection, analysis, and interpretation of data; in the writing of the manuscript; 
and in the decision to submit the manuscript for publication. Please also acknowledge 
anyone who contributed materials essential for the study. If a language editor has made 
significant revision of the manuscript, we recommend that you acknowledge the editor 
by name, where possible.  
The role of a scientific (medical) writer must be included in the acknowledgements 
section, including their source(s) of funding. We suggest wording such as 'We thank 
Jane Doe who provided medical writing services on behalf of XYZ Pharmaceuticals 
Ltd.' 
If you would like the names of the individual members of a collaboration Group to be 
searchable through their individual PubMed records, please ensure that the title of the 
collaboration Group is included on the title page and in the submission system and also 
include collaborating author names as the last paragraph of the “acknowledgements” 
section. Please add authors in the format First Name, Middle initial(s) (optional), Last 
Name. You can add institution or country information for each author if you wish, but 
this should be consistent across all authors. 
Please note that individual names may not be present in the PubMed record at the time 
a published article is initially included in PubMed as it takes PubMed additional time 
to code this information. 





Endnotes should be designated within the text using a superscript lowercase letter and 
all notes (along with their corresponding letter) should be included in the Endnotes 
section. Please format this section in a paragraph rather than a list. 
References 
All references, including URLs, must be numbered consecutively, in square brackets, 
in the order in which they are cited in the text, followed by any in tables or legends. 
Each reference must have an individual reference number. Please avoid excessive 
referencing. If automatic numbering systems are used, the reference numbers must be 
finalized and the bibliography must be fully formatted before submission. 
Only articles, clinical trial registration records and abstracts that have been published 
or are in press, or are available through public e-print/preprint servers, may be cited; 
unpublished abstracts, unpublished data and personal communications should not be 
included in the reference list, but may be included in the text and referred to as 
"unpublished observations" or "personal communications" giving the names of the 
involved researchers. Obtaining permission to quote personal communications and 
unpublished data from the cited colleagues is the responsibility of the author. 
Footnotes are not allowed, but endnotes are permitted. Journal abbreviations follow 
Index Medicus/MEDLINE. Citations in the reference list should include all named 
authors, up to the first six before adding 'et al.’ 
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Any in press articles cited within the references and necessary for the reviewers' 
assessment of the manuscript should be made available if requested by the editorial 
office. 
An Endnote style file is available. 
Examples of the Malaria Journal reference style are shown below. Please ensure that 
the reference style is followed precisely; if the references are not in the correct style 
they may have to be retyped and carefully proofread.  
All web links and URLs, including links to the authors' own websites, should be given 
a reference number and included in the reference list rather than within the text of the 
manuscript. They should be provided in full, including both the title of the site and the 
URL, as well as the date the site was accessed, in the following format: The Mouse 
Tumor Biology Database. http://tumor.informatics.jax.org/mtbwi/index.do. Accessed 
20 May 2013. If an author or group of authors can clearly be associated with a web 
link, such as for weblogs, then they should be included in the reference. 
Authors may wish to make use of reference management software to ensure that 
reference lists are correctly formatted. An example of such software is Papers, which 
is part of Springer Science+Business Media. 
 
Examples of the Malaria Journal reference style 
Article within a journal 
Smith JJ. The world of science. Am J Sci. 1999; 36:234-5. 
Article within a journal (no page numbers) 
Rohrmann S, Overvad K, Bueno-de-Mesquita HB, Jakobsen MU, Egeberg R, 
Tjønneland A, et al. Meat consumption and mortality - results from the European 
Prospective Investigation into Cancer and Nutrition. BMC Medicine. 2013;11:63. 
Article within a journal by DOI 
Slifka MK, Whitton JL. Clinical implications of dysregulated cytokine production. 
Dig J Mol Med. 2000; doi:10.1007/s801090000086. 
Article within a journal supplement 
Frumin AM, Nussbaum J, Esposito M. Functional asplenia: demonstration of splenic 
activity by bone marrow scan. Blood 1979;59 Suppl 1:26-32. 
Book chapter, or an article within a book 
Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. In: 
Bourne GH, Danielli JF, Jeon KW, editors. International review of cytology. 
London: Academic; 1980. p. 251-306. 
OnlineFirst chapter in a series (without a volume designation but with a DOI) 
Saito Y, Hyuga H. Rate equation approaches to amplification of enantiomeric excess 
and chiral symmetry breaking. Top Curr Chem. 2007. doi:10.1007/128_2006_108. 
Complete book, authored 
Blenkinsopp A, Paxton P. Symptoms in the pharmacy: a guide to the management of 
common illness. 3rd ed. Oxford: Blackwell Science; 1998. 
Online document 
Doe J. Title of subordinate document. In: The dictionary of substances and their 
effects. Royal Society of Chemistry. 1999. http://www.rsc.org/dose/title of 
subordinate document. Accessed 15 Jan 1999. 




Healthwise Knowledgebase. US Pharmacopeia, Rockville. 1998. 
http://www.healthwise.org. Accessed 21 Sept 1998. 
Supplementary material/private homepage 
Doe J. Title of supplementary material. 2000. http://www.privatehomepage.com. 
Accessed 22 Feb 2000. 
University site 
Doe, J: Title of preprint. http://www.uni-heidelberg.de/mydata.html (1999). 
Accessed 25 Dec 1999. 
FTP site 
Doe, J: Trivial HTTP, RFC2169. ftp://ftp.isi.edu/in-notes/rfc2169.txt (1999). 
Accessed 12 Nov 1999. 
Organization site 
ISSN International Centre: The ISSN register. http://www.issn.org (2006). Accessed 
20 Feb 2007. 
Dataset with persistent identifier 
Zheng L-Y, Guo X-S, He B, Sun L-J, Peng Y, Dong S-S, et al. Genome data from 
sweet and grain sorghum (Sorghum bicolor). GigaScience Database. 2011. 
http://dx.doi.org/10.5524/100012. 
Preparing illustrations and figures 
Illustrations should be provided as separate files, not embedded in the text file. Each 
figure should include a single illustration and should fit on a single page in portrait 
format. If a figure consists of separate parts, it is important that a single composite 
illustration file be submitted which contains all parts of the figure. There is no charge 
for the use of color figures. 
Please read our figure preparation guidelines for detailed instructions on maximising 
the quality of your figures. 
Formats 
The following file formats can be accepted: 
 PDF (preferred format for diagrams) 
 DOCX/DOC (single page only) 
 PPTX/PPT (single slide only) 
 EPS 





The legends should be included in the main manuscript text file at the end of the 
document, rather than being a part of the figure file. For each figure, the following 
information should be provided: Figure number (in sequence, using Arabic numerals 
- i.e. Figure 1, 2, 3 etc); short title of figure (maximum 15 words); detailed legend, up 
to 300 words. 
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Please note that it is the responsibility of the author(s) to obtain permission from 
the copyright holder to reproduce figures or tables that have previously been 
published elsewhere. 
Preparing a personal cover page 
If you wish to do so, you may submit an image which, in the event of publication, will 
be used to create a cover page for the PDF version of your article. The cover page will 
also display the journal logo, article title and citation details. The image may either be 
a figure from your manuscript or another relevant image. You must have permission 
from the copyright to reproduce the image. Images that do not meet our requirements 
will not be used. 
Images must be 300dpi and 155mm square (1831 x 1831 pixels for a raster image). 
Allowable formats - EPS, PDF (for line drawings), PNG, TIFF (for photographs and 
screen dumps), JPEG, BMP, DOC, PPT, CDX, TGF (ISIS/Draw). 
Preparing tables 
Each table should be numbered and cited in sequence using Arabic numerals (i.e. Table 
1, 2, 3 etc.). Tables should also have a title (above the table) that summarizes the whole 
table; it should be no longer than 15 words. Detailed legends may then follow, but they 
should be concise. Tables should always be cited in text in consecutive numerical 
order. 
Smaller tables considered to be integral to the manuscript can be pasted into the end 
of the document text file, in A4 portrait or landscape format. These will be typeset and 
displayed in the final published form of the article. Such tables should be formatted 
using the 'Table object' in a word processing program to ensure that columns of data 
are kept aligned when the file is sent electronically for review; this will not always be 
the case if columns are generated by simply using tabs to separate text. Columns and 
rows of data should be made visibly distinct by ensuring that the borders of each cell 
display as black lines. Commas should not be used to indicate numerical values. Color 
and shading may not be used; parts of the table can be highlighted using symbols or 
bold text, the meaning of which should be explained in a table legend. Tables should 
not be embedded as figures or spreadsheet files. 
Larger datasets or tables too wide for a landscape page can be uploaded separately as 
additional files. Additional files will not be displayed in the final, laid-out PDF of the 
article, but a link will be provided to the files as supplied by the author. 
Tabular data provided as additional files can be uploaded as an Excel spreadsheet (.xls 
) or comma separated values (.csv). As with all files, please use the standard file 
extensions. 
Preparing additional files 
Although Malaria Journal does not restrict the length and quantity of data included in 
an article, we encourage authors to provide datasets, tables, movies, or other 
information as additional files. 
Please note: All Additional files will be published along with the article. Do not 
include files such as patient consent forms, certificates of language editing, or revised 
versions of the main manuscript document with tracked changes. Such files should be 
sent by email to malariajournal@biomedcentral.com, quoting the Manuscript ID 
number. 
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Results that would otherwise be indicated as "data not shown" can and should be 
included as additional files. Since many weblinks and URLs rapidly become broken, 
Malaria Journal requires that supporting data are included as additional files, or 
deposited in a recognized repository. Please do not link to data on a 
personal/departmental website. The maximum file size for additional files is 20 MB 
each, and files will be virus-scanned on submission.  
Additional files can be in any format, and will be downloadable from the final 
published article as supplied by the author. We recommend CSV rather than PDF for 
tabular data. 
Certain supported files formats are recognized and can be displayed to the user in the 
browser. These include most movie formats (for users with the Quicktime plugin), 
mini-websites prepared according to our guidelines, chemical structure files (MOL, 
PDB), geographic data files (KML).  
If additional material is provided, please list the following information in a separate 
section of the manuscript text: 
 File name (e.g. Additional file 1) 
 File format including the correct file extension for example .pdf, .xls, .txt, .pptx 
(including name and a URL of an appropriate viewer if format is unusual) 
 Title of data 
 Description of data 
Additional files should be named "Additional file 1" and so on and should be 
referenced explicitly by file name within the body of the article, e.g. 'An additional 
movie file shows this in more detail [see Additional file 1]'. 
Additional file formats 
Ideally, file formats for additional files should not be platform-specific, and should be 
viewable using free or widely available tools. The following are examples of suitable 
formats. 
 Additional documentation  
o PDF (Adode Acrobat) 
 Animations  
o SWF (Shockwave Flash) 
 Movies  
o MP4 (MPEG 4) 
o MOV (Quicktime) 
 Tabular data  
o XLS, XLSX (Excel Spreadsheet) 
o CSV (Comma separated values) 
As with figure files, files should be given the standard file extensions. 
Mini-websites 
Small self-contained websites can be submitted as additional files, in such a way that 
they will be browsable from within the full text HTML version of the article. In order 
to do this, please follow these instructions: 
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1. Create a folder containing a starting file called index.html (or index.htm) in the 
root. 
2. Put all files necessary for viewing the mini-website within the folder, or sub-
folders. 
3. Ensure that all links are relative (ie "images/picture.jpg" rather than 
"/images/picture.jpg" or "http://yourdomain.net/images/picture.jpg" or 
"C:\Documents and Settings\username\My Documents\mini-
website\images\picture.jpg") and no link is longer than 255 characters. 
4. Access the index.html file and browse around the mini-website, to ensure that 
the most commonly used browsers (Internet Explorer and Firefox) are able to 
view all parts of the mini-website without problems, it is ideal to check this on 
a different machine. 
5. Compress the folder into a ZIP, check the file size is under 20 MB, ensure that 
index.html is in the root of the ZIP, and that the file has .zip extension, then 
submit as an additional file with your article. 
Style and language 
General 
Currently, Malaria Journal can only accept manuscripts written in English. Spelling 
should be US English or British English, but not a mixture. 
There is no explicit limit on the length of articles submitted, but authors are encouraged 
to be concise.  
Malaria Journal will not edit submitted manuscripts for style or language; reviewers 
may advise rejection of a manuscript if it is compromised by grammatical errors. 
Authors are advised to write clearly and simply, and to have their article checked by 
colleagues before submission. In-house copyediting will be minimal. Non-native 
speakers of English may choose to make use of a copyediting service. 
Help and advice on scientific writing 
The abstract is one of the most important parts of a manuscript. For guidance, please 
visit our page on Writing titles and abstracts for scientific articles.  
Tim Albert has produced for BioMed Central a list of tips for writing a scientific 
manuscript. American Scientist also provides a list of resources for science writing. 
For more detailed guidance on preparing a manuscript and writing in English, please 
visit the BioMed Central author academy. 
Abbreviations 
Abbreviations should be used as sparingly as possible. They should be defined when 
first used and a list of abbreviations can be provided following the main manuscript 
text. 
Typography 
 Please use double line spacing. 
 Type the text unjustified, without hyphenating words at line breaks. 
 Use hard returns only to end headings and paragraphs, not to rearrange lines. 
 Capitalize only the first word, and proper nouns, in the title. 
 All pages should be numbered. 
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 Use the Malaria Journal reference format. 
 Footnotes are not allowed, but endnotes are permitted. 
 Please do not format the text in multiple columns. 
 Greek and other special characters may be included. If you are unable to 
reproduce a particular special character, please type out the name of the symbol 
in full. Please ensure that all special characters used are embedded in the text, 
otherwise they will be lost during conversion to PDF. 
Units 
SI units should be used throughout (litre and molar are permitted, however). 
